Amgen, Inc.

2025 CDP Corporate Questionnaire 2025

Word version

Important: this export excludes unanswered questions
This document is an export of your organization's CDP questionnaire response. It contains all data points for questions that are answered or in progress. There may be questions or data points that you have been requested to provide, which are missing from this document because they are currently unanswered. Please note that it is your responsibility to verify that your questionnaire response is complete prior to submission. CDP will not be liable for any failure to do so.
Read full terms of disclosure

.

04/14/2026, 10:24 pm

Contents

C1. Introduction 1

(1.1) In which language are you submitting your response? 1

(1.2) Select the currency used for all financial information disclosed throughout your response. 1

(1.3) Provide an overview and introduction to your organization. 1

(1.4) State the end date of the year for which you are reporting data. For emissions data, indicate whether you will be providing emissions data for past reporting years 1

(1.4.1) What is your organization's annual revenue for the reporting period? 1

(1.5) Provide details on your reporting boundary. 1

(1.6) Does your organization have an ISIN code or another unique identifier (e.g., Ticker, CUSIP, etc.)? 1

(1.7) Select the countries/areas in which you operate. 1

(1.8) Are you able to provide geolocation data for your facilities? 1

(1.8.1) Please provide all available geolocation data for your facilities. 1

(1.24) Has your organization mapped its value chain? 1

(1.24.1) Have you mapped where in your direct operations or elsewhere in your value chain plastics are produced, commercialized, used, and/or disposed of? 1

C2. Identification, assessment, and management of dependencies, impacts, risks, and opportunities 1

(2.1) How does your organization define short-, medium-, and long-term time horizons in relation to the identification, assessment, and management of your environmental dependencies, impacts, risks, and opportunities? 1

(2.2) Does your organization have a process for identifying, assessing, and managing environmental dependencies and/or impacts? 1

(2.2.1) Does your organization have a process for identifying, assessing, and managing environmental risks and/or opportunities? 1

(2.2.2) Provide details of your organization's process for identifying, assessing, and managing environmental dependencies, impacts, risks, and/or opportunities. 1

(2.2.7) Are the interconnections between environmental dependencies, impacts, risks and/or opportunities assessed? 1

(2.3) Have you identified priority locations across your value chain? 1

(2.4) How does your organization define substantive effects on your organization? 1

(2.5) Does your organization identify and classify potential water pollutants associated with its activities that could have a detrimental impact on water ecosystems or human health? 1

(2.5.1) Describe how your organization minimizes the adverse impacts of potential water pollutants on water ecosystems or human health associated with your activities. 1

C3. Disclosure of risks and opportunities 1

(3.1) Have you identified any environmental risks which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future? 1

(3.1.1) Provide details of the environmental risks identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future. 1

(3.1.2) Provide the amount and proportion of your financial metrics from the reporting year that are vulnerable to the substantive effects of environmental risks. 1

(3.2) Within each river basin, how many facilities are exposed to substantive effects of water-related risks, and what percentage of your total number of facilities does this represent? 1

(3.3) In the reporting year, was your organization subject to any fines, enforcement orders, and/or other penalties for water-related regulatory violations? 1

(3.5) Are any of your operations or activities regulated by a carbon pricing system (i.e. ETS, Cap & Trade or Carbon Tax)? 1

(3.5.1) Select the carbon pricing regulation(s) which impact your operations. 1

(3.5.2) Provide details of each Emissions Trading Scheme (ETS) your organization is regulated by. 1

(3.5.3) Complete the following table for each of the tax systems you are regulated by. 1

(3.5.4) What is your strategy for complying with the systems you are regulated by or anticipate being regulated by? 1

(3.6) Have you identified any environmental opportunities which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future? 1

(3.6.1) Provide details of the environmental opportunities identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future. 1

(3.6.2) Provide the amount and proportion of your financial metrics in the reporting year that are aligned with the substantive effects of environmental opportunities. 1

C4. Governance 1

(4.1) Does your organization have a board of directors or an equivalent governing body? 1

(4.1.1) Is there board-level oversight of environmental issues within your organization? 1

(4.1.2) Identify the positions (do not include any names) of the individuals or committees on the board with accountability for environmental issues and provide details of the board's oversight of environmental issues. 1

(4.2) Does your organization's board have competency on environmental issues? 1

(4.3) Is there management-level responsibility for environmental issues within your organization? 1

(4.3.1) Provide the highest senior management-level positions or committees with responsibility for environmental issues (do not include the names of individuals). 1

(4.5) Do you provide monetary incentives for the management of environmental issues, including the attainment of targets? 1

(4.5.1) Provide further details on the monetary incentives provided for the management of environmental issues (do not include the names of individuals). 1

(4.6) Does your organization have an environmental policy that addresses environmental issues? 1

(4.6.1) Provide details of your environmental policies. 1

(4.10) Are you a signatory or member of any environmental collaborative frameworks or initiatives? 1

(4.11) In the reporting year, did your organization engage in activities that could directly or indirectly influence policy, law, or regulation that may (positively or negatively) impact the environment? 1

(4.11.2) Provide details of your indirect engagement on policy, law, or regulation that may (positively or negatively) impact the environment through trade associations or other intermediary organizations or individuals in the reporting year. 1

(4.12) Have you published information about your organization's response to environmental issues for this reporting year in places other than your CDP response? 1

(4.12.1) Provide details on the information published about your organization's response to environmental issues for this reporting year in places other than your CDP response. Please attach the publication. 1

C5. Business strategy 1

(5.1) Does your organization use scenario analysis to identify environmental outcomes? 1

(5.1.1) Provide details of the scenarios used in your organization's scenario analysis. 1

(5.1.2) Provide details of the outcomes of your organization's scenario analysis. 1

(5.2) Does your organization's strategy include a climate transition plan? 1

(5.3) Have environmental risks and opportunities affected your strategy and/or financial planning? 1

(5.3.1) Describe where and how environmental risks and opportunities have affected your strategy. 1

(5.3.2) Describe where and how environmental risks and opportunities have affected your financial planning. 1

(5.4) In your organization's financial accounting, do you identify spending/revenue that is aligned with your organization's climate transition? 1

(5.4.1) Quantify the amount and percentage share of your spending/revenue that is aligned with your organization's climate transition. 1

(5.9) What is the trend in your organization's water-related capital expenditure (CAPEX) and operating expenditure (OPEX) for the reporting year, and the anticipated trend for the next reporting year? 1

(5.10) Does your organization use an internal price on environmental externalities? 1

(5.10.1) Provide details of your organization's internal price on carbon. 1

(5.10.2) Provide details of your organization's internal price on water. 1

(5.11) Do you engage with your value chain on environmental issues? 1

(5.11.1) Does your organization assess and classify suppliers according to their dependencies and/or impacts on the environment? 1

(5.11.2) Does your organization prioritize which suppliers to engage with on environmental issues? 1

(5.11.5) Do your suppliers have to meet environmental requirements as part of your organization's purchasing process? 1

(5.11.6) Provide details of the environmental requirements that suppliers have to meet as part of your organization's purchasing process, and the compliance measures in place. 1

(5.11.7) Provide further details of your organization's supplier engagement on environmental issues. 1

(5.11.9) Provide details of any environmental engagement activity with other stakeholders in the value chain. 1
(5.12) Indicate any mutually beneficial environmental initiatives you could collaborate on with specific CDP Supply Chain members. 1
(5.13) Has your organization already implemented any mutually beneficial environmental initiatives due to CDP Supply Chain member engagement? 1

C6. Environmental Performance - Consolidation Approach 1
(6.1) Provide details on your chosen consolidation approach for the calculation of environmental performance data. 1

C7. Environmental performance - Climate Change 1
(7.1) Is this your first year of reporting emissions data to CDP? 1
(7.1.1) Has your organization undergone any structural changes in the reporting year, or are any previous structural changes being accounted for in this disclosure of emissions data? 1
(7.1.2) Has your emissions accounting methodology, boundary, and/or reporting year definition changed in the reporting year? 1
(7.1.3) Have your organization's base year emissions and past years' emissions been recalculated as a result of any changes or errors reported in 7.1.1 and/or 7.1.2? 1
(7.2) Select the name of the standard, protocol, or methodology you have used to collect activity data and calculate emissions. 1
(7.3) Describe your organization's approach to reporting Scope 2 emissions. 1
(7.4) Are there any sources (e.g. facilities, specific GHGs, activities, geographies, etc.) of Scope 1, Scope 2 or Scope 3 emissions that are within your selected reporting boundary which are not included in your disclosure? 1
(7.5) Provide your base year and base year emissions. 1
(7.6) What were your organization's gross global Scope 1 emissions in metric tons CO2e? 1
(7.7) What were your organization's gross global Scope 2 emissions in metric tons CO2e? 1
(7.8) Account for your organization's gross global Scope 3 emissions, disclosing and explaining any exclusions. 1
(7.8.1) Disclose or restate your Scope 3 emissions data for previous years. 1
(7.9) Indicate the verification/assurance status that applies to your reported emissions. 1
(7.9.1) Provide further details of the verification/assurance undertaken for your Scope 1 emissions, and attach the relevant statements. 1
(7.9.2) Provide further details of the verification/assurance undertaken for your Scope 2 emissions and attach the relevant statements. 1
(7.9.3) Provide further details of the verification/assurance undertaken for your Scope 3 emissions and attach the relevant statements. 1
(7.10) How do your gross global emissions (Scope 1 and 2 combined) for the reporting year compare to those of the previous reporting year? 1
(7.10.1) Identify the reasons for any change in your gross global emissions (Scope 1 and 2 combined), and for each of them specify how your emissions compare to the previous year. 1
(7.10.2) Are your emissions performance calculations in 7.10 and 7.10.1 based on a location-based Scope 2 emissions figure or a market-based Scope 2 emissions figure? 1

(7.12) Are carbon dioxide emissions from biogenic carbon relevant to your organization? 1
(7.15) Does your organization break down its Scope 1 emissions by greenhouse gas type? 1
(7.15.1) Break down your total gross global Scope 1 emissions by greenhouse gas type and provide the source of each used global warming potential (GWP). 1
(7.16) Break down your total gross global Scope 1 and 2 emissions by country/area. 1
(7.17) Indicate which gross global Scope 1 emissions breakdowns you are able to provide. 1
(7.17.2) Break down your total gross global Scope 1 emissions by business facility. 1
(7.17.3) Break down your total gross global Scope 1 emissions by business activity. 1
(7.20) Indicate which gross global Scope 2 emissions breakdowns you are able to provide. 1
(7.20.2) Break down your total gross global Scope 2 emissions by business facility. 1
(7.20.3) Break down your total gross global Scope 2 emissions by business activity. 1
(7.22) Break down your gross Scope 1 and Scope 2 emissions between your consolidated accounting group and other entities included in your response. 1
(7.23) Is your organization able to break down your emissions data for any of the subsidiaries included in your CDP response? 1
(7.27) What are the challenges in allocating emissions to different customers, and what would help you to overcome these challenges? 1
(7.28) Do you plan to develop your capabilities to allocate emissions to your customers in the future? 1
(7.29) What percentage of your total operational spend in the reporting year was on energy? 1
(7.30) Select which energy-related activities your organization has undertaken. 1
(7.30.1) Report your organization’s energy consumption totals (excluding feedstocks) in MWh. 1
(7.30.6) Select the applications of your organization’s consumption of fuel. 1
(7.30.7) State how much fuel in MWh your organization has consumed (excluding feedstocks) by fuel type. 1
(7.30.9) Provide details on the electricity, heat, steam, and cooling your organization has generated and consumed in the reporting year. 1
(7.30.14) Provide details on the electricity, heat, steam, and/or cooling amounts that were accounted for at a zero or near-zero emission factor in the market-based Scope 2 figure reported in 7.7. 1
(7.30.16) Provide a breakdown by country/area of your electricity/heat/steam/cooling consumption in the reporting year. 1
(7.45) Describe your gross global combined Scope 1 and 2 emissions for the reporting year in metric tons CO2e per unit currency total revenue and provide any additional intensity metrics that are appropriate to your business operations. 1
(7.52) Provide any additional climate-related metrics relevant to your business. 1
(7.53) Did you have an emissions target that was active in the reporting year? 1
(7.53.1) Provide details of your absolute emissions targets and progress made against those targets. 1
(7.54) Did you have any other climate-related targets that were active in the reporting year? 1

(7.54.1) Provide details of your targets to increase or maintain low-carbon energy consumption or production. 1
(7.54.2) Provide details of any other climate-related targets, including methane reduction targets. 1
(7.55) Did you have emissions reduction initiatives that were active within the reporting year? Note that this can include those in the planning and/or implementation phases. 1
(7.55.1) Identify the total number of initiatives at each stage of development, and for those in the implementation stages, the estimated CO2e savings. 1
(7.55.2) Provide details on the initiatives implemented in the reporting year in the table below. 1
(7.55.3) What methods do you use to drive investment in emissions reduction activities? 1
(7.73) Are you providing product level data for your organization's goods or services? 1
(7.74) Do you classify any of your existing goods and/or services as low-carbon products? 1
(7.74.1) Provide details of your products and/or services that you classify as low-carbon products. 1
(7.79) Has your organization retired any project-based carbon credits within the reporting year? 1
(7.79.1) Provide details of the project-based carbon credits retired by your organization in the reporting year. 1

C9. Environmental performance - Water security 1

(9.1) Are there any exclusions from your disclosure of water-related data? 1
(9.1.1) Provide details on these exclusions. 1
(9.2) Across all your operations, what proportion of the following water aspects are regularly measured and monitored? 1
(9.2.2) What are the total volumes of water withdrawn, discharged, and consumed across all your operations, how do they compare to the previous reporting year, and how are they forecasted to change? 1
(9.2.4) Indicate whether water is withdrawn from areas with water stress, provide the volume, how it compares with the previous reporting year, and how it is forecasted to change. 1
(9.2.7) Provide total water withdrawal data by source. 1
(9.2.8) Provide total water discharge data by destination. 1
(9.2.9) Within your direct operations, indicate the highest level(s) to which you treat your discharge. 1
(9.2.10) Provide details of your organization's emissions of nitrates, phosphates, pesticides, and other priority substances to water in the reporting year. 1
(9.3) In your direct operations and upstream value chain, what is the number of facilities where you have identified substantive water-related dependencies, impacts, risks, and opportunities? 1
(9.3.1) For each facility referenced in 9.3, provide coordinates, water accounting data, and a comparison with the previous reporting year. 1
(9.3.2) For the facilities in your direct operations referenced in 9.3.1, what proportion of water accounting data has been third party verified? 1
(9.4) Could any of your facilities reported in 9.3.1 have an impact on a requesting CDP supply chain member? 1

(9.4.1) Indicate which of the facilities referenced in 9.3.1 could impact a requesting CDP supply chain member. 1
(9.5) Provide a figure for your organization's total water withdrawal efficiency. 1
(9.12) Provide any available water intensity values for your organization's products or services. 1
(9.13) Do any of your products contain substances classified as hazardous by a regulatory authority? 1
(9.14) Do you classify any of your current products and/or services as low water impact? 1
(9.15) Do you have any water-related targets? 1
(9.15.1) Indicate whether you have targets relating to water pollution, water withdrawals, WASH, or other water-related categories. 1
(9.15.2) Provide details of your water-related targets and the progress made. 1

C10. Environmental performance - Plastics 1
(10.1) Do you have plastics-related targets, and if so what type? 1
(10.2) Indicate whether your organization engages in the following activities. 1
(10.4) Provide the total weight of plastic durable goods and durable components produced, sold and/or used, and indicate the raw material content. 1
(10.5) Provide the total weight of plastic packaging sold and/or used and indicate the raw material content. 1
(10.5.1) Indicate the circularity potential of the plastic packaging you sold and/or used. 1
(10.6) Provide the total weight of waste generated by the plastic you produce, commercialize, use and/or process and indicate the end-of-life management pathways. 1

C11. Environmental performance - Biodiversity 1
(11.2) What actions has your organization taken in the reporting year to progress your biodiversity-related commitments? 1
(11.3) Does your organization use biodiversity indicators to monitor performance across its activities? 1
(11.4) Does your organization have activities located in or near to areas important for biodiversity in the reporting year? 1

C13. Further information & sign off 1
(13.1) Indicate if any environmental information included in your CDP response (not already reported in 7.9.1/2/3, 8.9.1/2/3/4, and 9.3.2) is verified and/or assured by a third party? 1
(13.1.1) Which data points within your CDP response are verified and/or assured by a third party, and which standards were used? 1
(13.2) Use this field to provide any additional information or context that you feel is relevant to your organization's response. Please note that this field is optional and is not scored. 1
(13.3) Provide the following information for the person that has signed off (approved) your CDP response. 1
(13.4) Please indicate your consent for CDP to share contact details with the Pacific Institute to support content for its Water Action Hub website. 1

C1. Introduction

(1.1) In which language are you submitting your response?

Select from:

☑ English

(1.2) Select the currency used for all financial information disclosed throughout your response.

Select from:

☑ USD

(1.3) Provide an overview and introduction to your organization.

(1.3.2) Organization type

Select from:

☑ Publicly traded organization

(1.3.3) Description of organization

Amgen (referred to as “Amgen,” “we,” “our” or the "Company") is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing, and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Our belief—and the core of our strategy—is that innovative, highly differentiated medicines that provide large clinical benefits in addressing serious diseases are medicines that will not only help patients but also will help reduce the social and economic burden of disease in society today. Our strategy includes integrated activities intended to strengthen our competitive position in the industry. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world, and is developing a pipeline of medicines with breakaway potential. As a science-based company, Amgen has a long-standing objective to conduct environmentally responsible operations, and we regularly set targets to challenge ourselves to deliver further improvements. We continue to invest in sustainable operations to reach our 2027 environmental sustainability goals: Achieve carbon neutrality for Amgen-owned and -operated facilities and operations (Scope 1 and 2) (1,2), Reduce water consumption by 40% (3), and Reduce waste disposed by 75%. (3) As part of our 2027 environmental sustainability plan, in 2022, we established a Scope 3 supplier engagement target to engage with 73% of our suppliers by spend in key categories to support their adoption of science-based carbon emission reduction targets. For more information, visit www.amgen.com and follow us on www.twitter.com/amgen/. Footnotes: 1. Carbon neutrality goal is inclusive of our

acquisition of Horizon Therapeutics plc (Horizon) in October 2023. 2. The Science Based Targets initiative (SBTi) approved Amgen's Scope 1 and 2 carbon emissions reduction and Scope 3 supplier engagement targets in 2022. 3. Water and waste reductions are measured against a 2019 baseline and consider only verified reduction projects and not changes associated with the contraction or expansion of the Company (e.g., water and waste reduction measurements exclude Horizon).
[Fixed row]

(1.4) State the end date of the year for which you are reporting data. For emissions data, indicate whether you will be providing emissions data for past reporting years.

(1.4.1) End date of reporting year

12/31/2024

(1.4.2) Alignment of this reporting period with your financial reporting period

Select from:
☑ Yes

(1.4.3) Indicate if you are providing emissions data for past reporting years

Select from:
☑ Yes

(1.4.4) Number of past reporting years you will be providing Scope 1 emissions data for

Select from:
☑ 5 years

(1.4.5) Number of past reporting years you will be providing Scope 2 emissions data for

Select from:
☑ 5 years

(1.4.6) Number of past reporting years you will be providing Scope 3 emissions data for

Select from:

☑ 5 years

[Fixed row]

(1.4.1) What is your organization's annual revenue for the reporting period?

33424000000

(1.5) Provide details on your reporting boundary.

	Is your reporting boundary for your CDP disclosure the same as that used in your financial statements?
	Select from: ☑ Yes

[Fixed row]

(1.6) Does your organization have an ISIN code or another unique identifier (e.g., Ticker, CUSIP, etc.)?

ISIN code - bond

(1.6.1) Does your organization use this unique identifier?

Select from:

☑ No

ISIN code - equity

(1.6.1) Does your organization use this unique identifier?

Select from:

☑ Yes

(1.6.2) Provide your unique identifier

US0311621009

CUSIP number

(1.6.1) Does your organization use this unique identifier?

Select from:
☑ Yes

(1.6.2) Provide your unique identifier

031162100

Ticker symbol

(1.6.1) Does your organization use this unique identifier?

Select from:
☑ Yes

(1.6.2) Provide your unique identifier

AMGN

SEDOL code

(1.6.1) Does your organization use this unique identifier?

Select from:
☑ No

LEI number

(1.6.1) Does your organization use this unique identifier?

Select from:

☑ No

D-U-N-S number

(1.6.1) Does your organization use this unique identifier?

Select from:

☑ No

Other unique identifier

(1.6.1) Does your organization use this unique identifier?

Select from:

☑ No

[Add row]

(1.7) Select the countries/areas in which you operate.

Select all that apply

☑ China
☑ Egypt
☑ India
☑ Italy
☑ Japan
☑ Israel
☑ Mexico
☑ Spain
☑ Brazil
☑ Canada
☑ France
☑ Greece
☑ Turkey
☑ Austria

☑ Norway
☑ Poland
☑ Sweden
☑ Denmark
☑ Finland
☑ Germany
☑ Hungary
☑ Iceland
☑ Malaysia
☑ Portugal
☑ Slovakia
☑ Slovenia
☑ Thailand
☑ Philippines
☑ Puerto Rico
☑ Switzerland
☑ Saudi Arabia
☑ South Africa
☑ United Kingdom of Great Britain and Northern Ireland
☑ Belgium
☑ Croatia
☑ Czechia
☑ Ireland
☑ Morocco
☑ Romania
☑ Bulgaria
☑ Colombia
☑ Argentina
☑ Australia
☑ Lithuania
☑ Singapore
☑ Netherlands
☑ Taiwan, China
☑ Republic of Korea
☑ Russian Federation
☑ United Arab Emirates
☑ United States of America

(1.8) Are you able to provide geolocation data for your facilities?

	Are you able to provide geolocation data for your facilities?	Comment
	Select from: ☑ Yes, for all facilities	*Yes, for all facilities in scope*

[Fixed row]

(1.8.1) Please provide all available geolocation data for your facilities.

Row 1

(1.8.1.1) Identifier

West Greenwich, Rhode Island

(1.8.1.2) Latitude

41.657301

(1.8.1.3) Longitude

-71.569281

(1.8.1.4) Comment

Row 2

(1.8.1.1) Identifier

Cambridge, Massachusetts

(1.8.1.2) Latitude

42.366826

(1.8.1.3) Longitude

-71.089727

(1.8.1.4) Comment

Row 3

(1.8.1.1) Identifier

Thousand Oaks, California

(1.8.1.2) Latitude

34.191608

(1.8.1.3) Longitude

-118.920062

(1.8.1.4) Comment

Row 4

(1.8.1.1) Identifier

Louisville, Kentucky

(1.8.1.2) Latitude

38.20956

(1.8.1.3) Longitude

-85.533516

(1.8.1.4) Comment

Row 5

(1.8.1.1) Identifier

San Francisco, California

(1.8.1.2) Latitude

37.663442

(1.8.1.3) Longitude

-122.392067

(1.8.1.4) Comment

Row 6

(1.8.1.1) Identifier

Juncos, Puerto Rico

(1.8.1.2) Latitude

18.23702

(1.8.1.3) Longitude

-65.905113

(1.8.1.4) Comment

Row 7

(1.8.1.1) Identifier

Dun Laoghaire, Ireland

(1.8.1.2) Latitude

53.271119

(1.8.1.3) Longitude

-6.149951

(1.8.1.4) Comment

Row 8

(1.8.1.1) Identifier

Breda, Netherlands

(1.8.1.2) Latitude

51.588607

(1.8.1.3) Longitude

4.827929

(1.8.1.4) Comment

Row 9

(1.8.1.1) Identifier

Cambridge, United Kingdom

(1.8.1.2) Latitude

52.235541

(1.8.1.3) Longitude

0.142873

(1.8.1.4) Comment

Row 10

(1.8.1.1) Identifier

Burnaby, British Columbia

(1.8.1.2) Latitude

49.255059

(1.8.1.3) Longitude

-122.931961

(1.8.1.4) Comment

Row 11

(1.8.1.1) Identifier

Sao Paulo, Brazil

(1.8.1.2) Latitude

-23.618546

(1.8.1.3) Longitude

-46.774746

(1.8.1.4) Comment

Row 12

(1.8.1.1) Identifier

Singapore, Singapore

(1.8.1.2) Latitude

1.285921

(1.8.1.3) Longitude

103.626587

(1.8.1.4) Comment

Row 13

(1.8.1.1) Identifier

Deerfield, Illinois

(1.8.1.2) Latitude

42.15482

(1.8.1.3) Longitude

-87.87837

(1.8.1.4) Comment

Row 14

(1.8.1.1) Identifier

Waterford, Ireland

(1.8.1.2) Latitude

54.2421

(1.8.1.3) Longitude

-7.1755

(1.8.1.4) Comment

Row 15

(1.8.1.1) Identifier

Rockville, Maryland

(1.8.1.2) Latitude

39.10376

(1.8.1.3) Longitude

-77.18452

(1.8.1.4) Comment

[Add row]

(1.24) Has your organization mapped its value chain?

(1.24.1) Value chain mapped

Select from:

☑ Yes, we have mapped or are currently in the process of mapping our value chain

(1.24.2) Value chain stages covered in mapping

Select all that apply

☑ Upstream value chain

☑ Downstream value chain

(1.24.3) Highest supplier tier mapped

Select from:

☑ Tier 2 suppliers

(1.24.4) Highest supplier tier known but not mapped

Select from:

☑ Tier 3 suppliers

(1.24.7) Description of mapping process and coverage

Amgen uses supplier surveys to understand partial supplier Tier 2/3 context, and we collect Tier 1 supplier Business Continuity information. Amgen also uses a combination of internal and external software tools to map and monitor potential supply chain disruptions.
[Fixed row]

(1.24.1) Have you mapped where in your direct operations or elsewhere in your value chain plastics are produced, commercialized, used, and/or disposed of?

(1.24.1.1) Plastics mapping

Select from:

☑ Yes, we have mapped or are currently in the process of mapping plastics in our value chain

(1.24.1.2) Value chain stages covered in mapping

Select all that apply

☑ Direct operations

☑ Upstream value chain

☑ Downstream value chain

☑ End-of-life management

(1.24.1.4) End-of-life management pathways mapped

Select all that apply

☑ Recycling
☑ Waste to Energy
☑ Incineration
☑ Landfill
[Fixed row]

Public

C2. Identification, assessment, and management of dependencies, impacts, risks, and opportunities

(2.1) How does your organization define short-, medium-, and long-term time horizons in relation to the identification, assessment, and management of your environmental dependencies, impacts, risks, and opportunities?

Short-term

(2.1.1) From (years)

0

(2.1.3) To (years)

3

(2.1.4) How this time horizon is linked to strategic and/or financial planning

The definition of short-, medium-, and long-term from an enterprise perspective will depend upon the specifics of the topic, risk, initiative, or strategy at hand. For climate-related issues, Amgen's Operations team has defined present day through 2027 as "short-term" because that is the length of time remaining for our current sustainability performance targets.

Medium-term

(2.1.1) From (years)

4

(2.1.3) To (years)

11

(2.1.4) How this time horizon is linked to strategic and/or financial planning

For climate-related issues, Amgen's Operations team has defined "medium-term" as the next upcoming performance period for sustainability targets.

Long-term

(2.1.1) From (years)

12

(2.1.2) Is your long-term time horizon open ended?

Select from:

☑ No

(2.1.3) To (years)

27

(2.1.4) How this time horizon is linked to strategic and/or financial planning

To include the long-term aspects of risk screening for future climate scenarios (through 2050), in alignment with international regulations and guidance, for climate-related issues Amgen's Operations team has defined "long-term" to represent a time frame that is two planning cycles ahead of our current sustainability performance targets.
[Fixed row]

(2.2) Does your organization have a process for identifying, assessing, and managing environmental dependencies and/or impacts?

	Process in place	Dependencies and/or impacts evaluated in this process
	Select from:	*Select from:*

	Process in place	Dependencies and/or impacts evaluated in this process
	☑ Yes	☑ Both dependencies and impacts

[Fixed row]

(2.2.1) Does your organization have a process for identifying, assessing, and managing environmental risks and/or opportunities?

	Process in place	Risks and/or opportunities evaluated in this process	Is this process informed by the dependencies and/or impacts process?
	Select from: ☑ Yes	*Select from:* ☑ Both risks and opportunities	*Select from:* ☑ Yes

[Fixed row]

(2.2.2) Provide details of your organization's process for identifying, assessing, and managing environmental dependencies, impacts, risks, and/or opportunities.

Row 1

(2.2.2.1) Environmental issue

Select all that apply

☑ Climate change

(2.2.2.2) Indicate which of dependencies, impacts, risks, and opportunities are covered by the process for this environmental issue

Select all that apply

☑ Dependencies

☑ Impacts

☑ Risks

☑ Opportunities

(2.2.2.3) Value chain stages covered

Select all that apply

☑ Direct operations

☑ Upstream value chain

☑ Downstream value chain

(2.2.2.4) Coverage

Select from:

☑ Partial

(2.2.2.5) Supplier tiers covered

Select all that apply

☑ Tier 1 suppliers

(2.2.2.7) Type of assessment

Select from:

☑ Qualitative and quantitative

(2.2.2.8) Frequency of assessment

Select from:

☑ More than once a year

(2.2.2.9) Time horizons covered

Select all that apply

☑ Short-term

☑ Medium-term

☑ Long-term

(2.2.2.10) Integration of risk management process

Select from:

☑ Integrated into multi-disciplinary organization-wide risk management process

(2.2.2.11) Location-specificity used

Select all that apply

☑ Site-specific

☑ Local

☑ Sub-national

(2.2.2.12) Tools and methods used

Enterprise Risk Management

☑ Enterprise Risk Management

☑ Internal company methods

International methodologies and standards

☑ Life Cycle Assessment

Other

☑ Scenario analysis

☑ External consultants

☑ Other, please specify **:EcoVadis**

☑ Materiality assessment
☑ Internal company methods
☑ Partner and stakeholder consultation/analysis

(2.2.2.13) Risk types and criteria considered

Acute physical
☑ Drought
☑ Tornado
☑ Wildfires
☑ Heat waves
☑ Cold wave/frost
☑ Cyclones, hurricanes, typhoons
☑ Heavy precipitation (rain, hail, snow/ice)
☑ Flood (coastal, fluvial, pluvial, ground water)
☑ Storm (including blizzards, dust, and sandstorms)

Chronic physical
☑ Changing precipitation patterns and types (rain, hail, snow/ice)
☑ Changing temperature (air, freshwater, marine water)
☑ Changing wind patterns
☑ Heat stress
☑ Sea level rise

Policy
☑ Carbon pricing mechanisms
☑ Changes to international law and bilateral agreements
☑ Changes to national legislation

Market
☑ Availability and/or increased cost of raw materials
☑ Changing customer behavior

Reputation
☑ Increased partner and stakeholder concern and partner and stakeholder negative feedback

☑ Negative press coverage related to support of projects or activities with negative impacts on the environment (e.g. GHG emissions, deforestation & conversion, water stress)

Technology

☑ Transition to lower emissions technology and products

Liability

☑ Non-compliance with regulations

(2.2.2.14) Partners and stakeholders considered

Select all that apply

☑ NGOs

☑ Customers

☑ Employees

☑ Investors

☑ Suppliers

☑ Regulators

☑ Local communities

☑ Indigenous peoples

(2.2.2.15) Has this process changed since the previous reporting year?

Select from:

☑ No

(2.2.2.16) Further details of process

Situation: Climate-related risks are managed globally by our Operations Strategy and Business Resilience group in collaboration with our Environmental Sustainability group, which sits in the Global Engineering Department. Designated Amgen site business resilience leaders and key operations stakeholders within Operations, Global Distribution, External Supply, Global Crisis Management, Environment, Health & Safety (EHS), Global Engineering, and Quality routinely document all relevant risks and mitigation plans within local registries. Risk registries and continuity plans are reviewed on an annual basis; risks may reflect financial, reputational, operational, or regulatory impact. The Board of Directors receives regular risk reporting from senior management, including an annual detailed review of the Enterprise Risk Management program and key enterprise-level and emerging risks, as well as during the Board's strategic planning activities, budget reviews and approvals, capital plan reviews and approvals, and through reviews of compliance issues at the applicable Board committees, as appropriate. Task: To align further with international financial disclosure frameworks, including the Task Force on Climate-related Financial Disclosures (TCFD) and regulations such as the Corporate Sustainability Reporting Directive (CSRD), in 2023, the global team worked to define climate risk scenarios, assess transition and physical risks, and develop and

socialize recommendations. The scenarios were selected with climate, water and biodiversity risks and dependencies in mind. Action: Stakeholders from functions across the enterprise participated in a series of workshops to identify priority climate risks and opportunities. For transition risks, we identified regulatory, market, technology and reputational drivers and identified the vulnerability for different business units' strategies and activities. For physical risks, we performed risk assessments for fifteen Amgen sites and six supplier sites located around the globe to determine climate exposure across scenarios and time horizons. Further assessment was conducted in 2024, with a focus on Amgen's exposure to 100- and 500- year climate risk events. Result: The work revealed that Amgen sites are appropriately mitigated in the near term through current risk and business continuity measures. The supplementary analysis in 2024 showed that Amgen sites are well prepared for 100-year climate risk events, but the severity of 500-year risk events could present financial risk and may require reassessment of site infrastructure in the near-term or medium-term. New regulations, the ability of supply chains to meet new requirements, and the availability of low-emission technology are potential near-term transition risks for Amgen. Resulting efforts to mitigate transition risks include engaging with suppliers on their decarbonization efforts, increasing electrification of our processes, and increasing our use of renewable energy. Furthermore, as a result of this work, the business resilience program was updated to include climate change as a standalone risk that is tracked in the Operations Network Risk Assessment, which considers i) operational risk management; ii) site-level risk management; iii) business continuity; and iv) business intelligence. The program now considers medium- and long-term risks, particularly involving climate change projections, in the overall risk management process.

Row 2

(2.2.2.1) Environmental issue

Select all that apply

☑ Water

(2.2.2.2) Indicate which of dependencies, impacts, risks, and opportunities are covered by the process for this environmental issue

Select all that apply

☑ Risks

☑ Opportunities

(2.2.2.3) Value chain stages covered

Select all that apply

☑ Direct operations

☑ Upstream value chain

☑ Downstream value chain

(2.2.2.4) Coverage

Select from:

☑ Partial

(2.2.2.5) Supplier tiers covered

Select all that apply

☑ Tier 1 suppliers

(2.2.2.7) Type of assessment

Select from:

☑ Qualitative and quantitative

(2.2.2.8) Frequency of assessment

Select from:

☑ Annually

(2.2.2.9) Time horizons covered

Select all that apply

☑ Short-term

☑ Medium-term

☑ Long-term

(2.2.2.10) Integration of risk management process

Select from:

☑ Integrated into multi-disciplinary organization-wide risk management process

(2.2.2.11) Location-specificity used

Select all that apply

☑ Site-specific

☑ Local

☑ Sub-national

(2.2.2.12) Tools and methods used

Commercially/publicly available tools

☑ EcoVadis

☑ WRI Aqueduct

☑ WWF Water Risk Filter

Enterprise Risk Management

☑ Enterprise Risk Management

(2.2.2.13) Risk types and criteria considered

Acute physical

☑ Drought

☑ Tornado

☑ Wildfires

☑ Heat waves

☑ Cold wave/frost

☑ Cyclones, hurricanes, typhoons

☑ Heavy precipitation (rain, hail, snow/ice)

☑ Flood (coastal, fluvial, pluvial, ground water)

☑ Storm (including blizzards, dust, and sandstorms)

Chronic physical

☑ Water stress

☑ Water quality at a basin/catchment level

Market

☑ Availability and/or increased cost of raw materials

☑ Inadequate access to water, sanitation, and hygiene services (WASH)

Reputation

☑ Stakeholder conflicts concerning water resources at a basin/catchment level

Technology

☑ Transition to water efficient and low water intensity technologies and products

(2.2.2.14) Partners and stakeholders considered

Select all that apply

☑ NGOs

☑ Customers

☑ Employees

☑ Investors

☑ Suppliers

☑ Regulators

☑ Local communities

☑ Indigenous peoples

☑ Water utilities at a local level

☑ Other water users at the basin/catchment level

☑ Other, please specify :The stakeholders listed above are our key stakeholders, however, we continue to consider other stakeholders as they are identified.

(2.2.2.15) Has this process changed since the previous reporting year?

Select from:

☑ No

(2.2.2.16) Further details of process

Amgen takes a holistic approach to our water-related risk assessment to improve our water stewardship in the communities in which we operate globally and to support our mission to serve patients. Amgen understands that water issues are highly localized and specific to their respective geographical locations. Our water-related risk assessment enables us to analyze and develop water-reduction plans, including water-efficiency engineering projects, that prioritize Amgen locations where water stress is the most significant. The tools we employ enable us to consider a robust range of water risks, such as flooding, water quality, regulatory risks, reputational risks, and access to water and sanitation. According to the World Wildlife Fund (WWF) Water Risk Filter and the World Resources Institute (WRI) Aqueduct Water Risk Atlas tools, our sites in Thousand Oaks (California), San Francisco (California), West Greenwich (Rhode Island), Cambridge (Massachusetts), Juncos (Puerto Rico), Breda (Netherlands), Burnaby (Canada), Cambridge (UK), Deerfield (Illinois), Singapore, New Albany (Ohio), and Louisville (Kentucky) are located in geographical areas that experienced water stress in 2024. Using both tools, we identified these sites as water-stressed locations using the tools' risk scores of Medium Risk or higher on the WWF Water Risk Filter tool and a Medium-High (20-40%) or higher on the WRI Aqueduct Water Risk Atlas. Amgen's process annually identifies and assesses water-related risks to our operations such as droughts and impacts on water quantity and quality. Identified risks are evaluated based on their potential for financial and operational impact, their probability, and the expected time horizon and compared cross-functionally. The impact severity can

be inferred from the estimation of magnitude, frequency, and duration of adverse events. The estimated impact of each risk drives corresponding action that may include risk management activities ranging from water infrastructure efficiency initiatives, water supply monitoring, and water conserving operational controls. All Amgen staff are provided with water that is safe for drinking, sanitation, and hygiene and sourced from local drinking water purveyors. We engage with stakeholders in our communities where we operate, given the importance of water as a resource. We communicate expectations to our key suppliers regarding water risks through our Supplier Code of Conduct and engage through our relationship with a third-party service provider. Our #HealthyPlanet program recognizes staff who create programs/activities that support our sustainability goals. Employees can earn rewards from activities such as implementing a sustainability policy practice for a department or training employees to use equipment more efficiently to reduce our environmental footprint, including our water usage. Our staff also volunteer in their communities. For almost two decades, we have participated in the International Coastal Cleanup initiative. Nineteen Amgen sites joined the effort in 2024 to clean up beaches, parks, or rivers in their communities. The California Coastal Commission has recognized Amgen volunteers for their public service in protecting the natural resources of the California coast

Row 3

(2.2.2.1) Environmental issue

Select all that apply

☑ Biodiversity

(2.2.2.2) Indicate which of dependencies, impacts, risks, and opportunities are covered by the process for this environmental issue

Select all that apply

☑ Risks

☑ Opportunities

(2.2.2.3) Value chain stages covered

Select all that apply

☑ Direct operations

☑ Upstream value chain

☑ Downstream value chain

(2.2.2.4) Coverage

Select from:

☑ Partial

(2.2.2.5) Supplier tiers covered

Select all that apply

☑ Tier 1 suppliers

(2.2.2.7) Type of assessment

Select from:

☑ Qualitative only

(2.2.2.8) Frequency of assessment

Select from:

☑ Annually

(2.2.2.9) Time horizons covered

Select all that apply

☑ Short-term

(2.2.2.10) Integration of risk management process

Select from:

☑ A specific environmental risk management process

(2.2.2.11) Location-specificity used

Select all that apply

☑ Site-specific

☑ Local

☑ Sub-national

(2.2.2.12) Tools and methods used

Commercially/publicly available tools

☑ Encore tool

☑ IBAT – Integrated Biodiversity Assessment Tool

☑ LEAP (Locate, Evaluate, Assess and Prepare) approach, TNFD

☑ TNFD – Taskforce on Nature-related Financial Disclosures

☑ WWF Biodiversity Risk Filter

Other

☑ Other, please specify :EcoVadis

(2.2.2.13) Risk types and criteria considered

Acute physical

☑ Drought

☑ Tornado

☑ Wildfires

☑ Heat waves

☑ Cold wave/frost

☑ Cyclones, hurricanes, typhoons

☑ Heavy precipitation (rain, hail, snow/ice)

☑ Flood (coastal, fluvial, pluvial, ground water)

☑ Storm (including blizzards, dust, and sandstorms)

Chronic physical

☑ Sea level rise

☑ Other chronic physical driver, please specify **:Heat Stress; Changing Wind Patterns; Scarcity of land resources**

☑ Change in land-use

☑ Increased ecosystem vulnerability

☑ Changing temperature (air, freshwater, marine water)

☑ Changing precipitation patterns and types (rain, hail, snow/ice)

(2.2.2.14) Partners and stakeholders considered

Select all that apply

☑ NGOs
☑ Customers
☑ Employees
☑ Investors
☑ Suppliers
☑ Regulators
☑ Local communities
☑ Indigenous peoples

(2.2.2.15) Has this process changed since the previous reporting year?

Select from:

☑ No

(2.2.2.16) Further details of process

In 2024, Amgen employed the WWF Biodiversity Risk Filter and internal assessment tools to identify location and site-type risk factors, building on the Taskforce on Nature-related Financial Disclosures (TNFD) gap analysis and screening in 2023. Amgen also published an updated Biodiversity Position Statement in 2024, articulating Amgen's biodiversity context, strategy, objectives and progress. Amgen also performed a site-region biodiversity assessment for Thousand Oaks (California) (headquarters), Puerto Rico and Singapore (manufacturing) to identify biodiversity protection areas and species at risk in site biomes and to support stakeholder engagement. These assessments are helping Amgen understand possible site-specific biodiversity risks and opportunities and will form the foundation for prioritizing future action.
[Add row]

(2.2.7) Are the interconnections between environmental dependencies, impacts, risks and/or opportunities assessed?

(2.2.7.1) Interconnections between environmental dependencies, impacts, risks and/or opportunities assessed

Select from:

☑ Yes

(2.2.7.2) Description of how interconnections are assessed

Amgen's scenario analysis includes climate and water risks, and opportunities, such as Resource Efficiency, New Financing, and Use of Low Carbon Energy Sources, and aims to address transition risks such as Carbon Pricing Mechanism and Transition to Lower Emission Technology/Products. Amgen seeks to align with the Taskforce on Nature-related Financial Disclosures and is primarily employing the WWF Biodiversity Risk Filter tool to screen different nature and biodiversity risks

and dependencies, including those impacted by climate change. In 2023, Amgen screened 11 Amgen facilities and six supplier sites, and, in 2024, Amgen focused on assessments at two key Amgen sites. This assessment is informing future risk assessment work that will consider climate change and biodiversity in parallel.
[Fixed row]

(2.3) Have you identified priority locations across your value chain?

(2.3.1) Identification of priority locations

Select from:

☑ Yes, we are currently in the process of identifying priority locations

(2.3.2) Value chain stages where priority locations have been identified

Select all that apply

☑ Direct operations

☑ Upstream value chain

☑ Downstream value chain

(2.3.3) Types of priority locations identified

Sensitive locations

☑ Areas important for biodiversity

☑ Areas of high ecosystem integrity

☑ Areas of rapid decline in ecosystem integrity

☑ Areas of limited water availability, flooding, and/or poor quality of water

☑ Areas of importance for ecosystem service provision

Locations with substantive dependencies, impacts, risks, and/or opportunities

☑ Locations with substantive dependencies, impacts, risks, and/or opportunities relating to forests

☑ Locations with substantive dependencies, impacts, risks, and/or opportunities relating to water

☑ Locations with substantive dependencies, impacts, risks, and/or opportunities relating to biodiversity

(2.3.4) Description of process to identify priority locations

Amgen is primarily employing the WWF Biodiversity Risk Filter tool to screen different nature and biodiversity risks and dependencies

(2.3.5) Will you be disclosing a list/spatial map of priority locations?

Select from:

☑ No, we do not have a list/geospatial map of priority locations

[Fixed row]

(2.4) How does your organization define substantive effects on your organization?

Risks

(2.4.1) Type of definition

Select all that apply

☑ Qualitative

☑ Quantitative

(2.4.2) Indicator used to define substantive effect

Select from:

☑ Direct operating costs

(2.4.3) Change to indicator

Select from:

☑ Absolute increase

(2.4.5) Absolute increase/ decrease figure

500000

(2.4.6) Metrics considered in definition

Select all that apply

☑ Likelihood of effect occurring

(2.4.7) Application of definition

Amgen Strategic Planning and Risk within Operations defines substantive risks by categorizing and assessing the severity of impacts across various domains: personnel injury or illness, environmental impact, market interruption, business interruption, clinical trial delay, financial impact, and compliance. The severity is rated on a scale from 1 (Insignificant) to 9 (Severe), with specific criteria for each level. This wide-ranging approach helps to ensure that potential risks, particularly those related to climate change, are systematically assessed and managed, helping the organization to mitigate and respond effectively to various levels of risk. Insignificant risks (1 on the scale) are defined as no injuries or health impacts, no environmental impact or nonconformance, no market interruption, business delay of less than a day, no clinical program impact, financial impact under $500K, and no compliance issues. The outcomes of such operational risk assessments should not be construed as a characterization regarding materiality from a U.S. public company reporting perspective. Such metrics are the starting point for assessing importance and further analysis that considers qualitative and other factors can influence the results of any assessment. For further discussion of risks and uncertainties that may have an adverse effect on our business, please see the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

Opportunities

(2.4.1) Type of definition

Select all that apply

☑ Qualitative

(2.4.6) Metrics considered in definition

Select all that apply

☑ Likelihood of effect occurring

(2.4.7) Application of definition

The substantive effects of opportunities are currently not measured.

Risks

(2.4.1) Type of definition

Select all that apply

☑ Qualitative

☑ Quantitative

(2.4.2) Indicator used to define substantive effect

Select from:

☑ Direct operating costs

(2.4.3) Change to indicator

Select from:

☑ Absolute increase

(2.4.5) Absolute increase/ decrease figure

1000000

(2.4.6) Metrics considered in definition

Select all that apply

☑ Likelihood of effect occurring

(2.4.7) Application of definition

Amgen Strategic Planning and Risk within Operations defines substantive risks by categorizing and assessing the severity of impacts across various domains: personnel injury or illness, environmental impact, market interruption, business interruption, clinical trial delay, financial impact, and compliance. The severity is rated on a scale from 1 (Insignificant) to 9 (Severe), with specific criteria for each level. This wide-ranging approach helps to ensure that potential risks, particularly those related to climate change, are systematically assessed and managed, helping the organization to mitigate and respond effectively to various levels of risk. Minor risks (3 on the scale) include minor injuries requiring first aid, process failures that hinder pollution control, minimal market interruption (finished goods inventory 0-2 MFC), business delay of 1 day to 2 weeks, delayed Phase 2 clinical program enrollment, financial impact between $500K and $1M, and potential regulatory observations. The outcomes of such operational risk assessments should not be construed as a characterization regarding materiality from a U.S. public company reporting perspective. Such metrics are the starting point for assessing importance and further analysis that considers qualitative and other factors can influence the results of

any assessment. For further discussion of risks and uncertainties that may have an adverse effect on our business, please see the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

Risks

(2.4.1) Type of definition

Select all that apply

☑ Qualitative

☑ Quantitative

(2.4.2) Indicator used to define substantive effect

Select from:

☑ Direct operating costs

(2.4.3) Change to indicator

Select from:

☑ Absolute increase

(2.4.5) Absolute increase/ decrease figure

10000000

(2.4.6) Metrics considered in definition

Select all that apply

☑ Likelihood of effect occurring

(2.4.7) Application of definition

Amgen Strategic Planning and Risk within Operations defines substantive risks by categorizing and assessing the severity of impacts across various domains: personnel injury or illness, environmental impact, market interruption, business interruption, clinical trial delay, financial impact, and compliance. The severity is rated on a scale from 1 (Insignificant) to 9 (Severe), with specific criteria for each level. This wide-ranging approach helps to ensure that potential risks, particularly those

related to climate change, are systematically assessed and managed, helping the organization to mitigate and respond effectively to various levels of risk. Moderate risks (5 on the scale) are defined as injuries or moderate health impacts, process failures causing repeated nonconformances with environmental release, certain SKU interruptions with product availability, business delay of 2 weeks to 1 month, delayed or halted Phase 3 trials, financial impact between $1M and $10M, and systemic regulatory issues impacting multiple Quality Systems. The outcomes of such operational risk assessments should not be construed as a characterization regarding materiality from a U.S. public company reporting perspective. Such metrics are the starting point for assessing importance and further analysis that considers qualitative and other factors can influence the results of any assessment. For further discussion of risks and uncertainties that may have an adverse effect on our business, please see the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

Risks

(2.4.1) Type of definition

Select all that apply

☑ Qualitative

☑ Quantitative

(2.4.2) Indicator used to define substantive effect

Select from:

☑ Direct operating costs

(2.4.3) Change to indicator

Select from:

☑ Absolute increase

(2.4.5) Absolute increase/ decrease figure

20000000

(2.4.6) Metrics considered in definition

Select all that apply

☑ Likelihood of effect occurring

(2.4.7) Application of definition

Amgen Strategic Planning and Risk within Operations defines substantive risks by categorizing and assessing the severity of impacts across various domains: personnel injury or illness, environmental impact, market interruption, business interruption, clinical trial delay, financial impact, and compliance. The severity is rated on a scale from 1 (Insignificant) to 9 (Severe), with specific criteria for each level. This wide-ranging approach helps to ensure that potential risks, particularly those related to climate change, are systematically assessed and managed, helping the organization to mitigate and respond effectively to various levels of risk. Major risks (7 on scale) are defined as one or more injuries requiring hospitalization or multiple OSHA-recordable incidents, significant process failures with potential harm to health or environment, market interruption up to 1 month or product launch delay over 6 months, business delay of 1 to 4 months, Phase 3 trial stoppages during enrollment, financial impact between $10M and $20M, and significant regulatory commitments or warning letters. The outcomes of such operational risk assessments should not be construed as a characterization regarding materiality from a U.S. public company reporting perspective. Such metrics are the starting point for assessing importance and further analysis that considers qualitative and other factors can influence the results of any assessment. For further discussion of risks and uncertainties that may have an adverse effect on our business, please see the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission.

Risks

(2.4.1) Type of definition

Select all that apply

☑ Qualitative

☑ Quantitative

(2.4.2) Indicator used to define substantive effect

Select from:

☑ Direct operating costs

(2.4.3) Change to indicator

Select from:

☑ Absolute increase

(2.4.5) Absolute increase/ decrease figure

20000001

(2.4.6) Metrics considered in definition

Select all that apply

☑ Likelihood of effect occurring

(2.4.7) Application of definition

Amgen Strategic Planning and Risk within Operations defines substantive risks by categorizing and assessing the severity of impacts across various domains: personnel injury or illness, environmental impact, market interruption, business interruption, clinical trial delay, financial impact, and compliance. The severity is rated on a scale from 1 (Insignificant) to 9 (Severe), with specific criteria for each level. This wide-ranging approach helps to ensure that potential risks, particularly those related to climate change, are systematically assessed and managed, helping the organization to mitigate and respond effectively to various levels of risk. Severe risks (9 on the scale) are defined as fatalities, process failures creating imminent hazards, market interruption over 1 month, business delay over 4 months, halted Phase 3 trials after enrollment completion, financial impact exceeding $20M, and potential product recalls or withholding of product approvals. The outcomes of such operational risk assessments should not be construed as a characterization regarding materiality from a U.S. public company reporting perspective. Such metrics are the starting point for assessing importance and further analysis that considers qualitative and other factors can influence the results of any assessment. For further discussion of risks and uncertainties that may have an adverse effect on our business, please see the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2024, filed with the Securities and Exchange Commission.
[Add row]

(2.5) Does your organization identify and classify potential water pollutants associated with its activities that could have a detrimental impact on water ecosystems or human health?

(2.5.1) Identification and classification of potential water pollutants

Select from:

☑ Yes, we identify and classify our potential water pollutants

(2.5.2) How potential water pollutants are identified and classified

As part of our research and development (R&D), manufacturing change management, and new product introduction processes, Amgen assesses and characterizes potential water pollutants in wastewater to help to ensure safe and compliant waste and wastewater management. We characterize the waste streams and manage them by either substitution, onsite pretreatment, or management of the waste streams at an offsite waste disposal facility. We also perform project-related environmental design reviews and risk assessments on new or modified processes.
[Fixed row]

(2.5.1) Describe how your organization minimizes the adverse impacts of potential water pollutants on water ecosystems or human health associated with your activities.

Row 1

(2.5.1.1) Water pollutant category

Select from:

☑ Phosphates

(2.5.1.2) Description of water pollutant and potential impacts

Amgen has identified phosphorus and chloride sources within our manufacturing processes. We strive to minimize the discharge of phosphates to publicly owned treatment works by taking actions to minimize their use, implement onsite pretreatment, or segregate them for offsite disposal. Wastewater that is not properly treated has the potential to harm human health and the natural environment. All our facilities are expected to maintain the necessary compliance required by their local regulatory authorities in their respective geographical location.

(2.5.1.3) Value chain stage

Select all that apply

☑ Direct operations

(2.5.1.4) Actions and procedures to minimize adverse impacts

Select all that apply

☑ Industrial and chemical accidents prevention, preparedness, and response

☑ Provision of best practice instructions on product use

☑ Discharge treatment using sector-specific processes to ensure compliance with regulatory requirements

☑ Upgrading of process equipment/methods

(2.5.1.5) Please explain

Amgen characterizes the waste streams and manages them by either substitution or onsite pretreatment, or we manage the waste streams at an offsite waste disposal facility. Amgen also mandates that new chemicals brought onsite are assessed by our Environmental, Health and Safety department prior to procurement.

Row 2

(2.5.1.1) Water pollutant category

Select from:

☑ Microplastics and plastic particles

(2.5.1.2) Description of water pollutant and potential impacts

Wastewater that is not properly treated has the potential to harm human health and the natural environment. Amgen utilizes a variety of plastics in our R&D, manufacturing, final product packaging, and other onsite operations such as our cafeteria food containers. We have begun conducting life cycle analyses related to our use of plastics, and we strive to reduce or substitute plastics where possible. All our facilities are expected to maintain the necessary compliance required by their local regulatory authorities in their respective geographical location.

(2.5.1.3) Value chain stage

Select all that apply

☑ Direct operations

☑ Other, please specify :Product Use Phase

(2.5.1.4) Actions and procedures to minimize adverse impacts

Select all that apply

☑ Beyond compliance with regulatory requirements

(2.5.1.5) Please explain

We have begun conducting life cycle analyses related to our use of plastics, and we strive to reduce or substitute plastics where possible. We have implemented robust plastics recycling programs within our R&D, manufacturing operations, and administrative areas. We engage with our employees and surrounding communities through educational and volunteer outreach events such as International Coastal Cleanup Day and onsite Earth Day fairs.

Row 3

(2.5.1.1) Water pollutant category

Select from:

☑ Other synthetic organic compounds

(2.5.1.2) Description of water pollutant and potential impacts

Amgen utilizes a variety of organic solvents in our small molecule R&D and manufacturing operations. We strive to minimize potential impacts from these solvents and synthetic organic compounds by segregating and managing these regulated waste products at offsite disposal facilities. Wastewater that is not properly treated has the potential to harm human health and the natural environment. All our facilities are expected to maintain the necessary compliance required by their local regulatory authorities in their respective geographical location.

(2.5.1.3) Value chain stage

Select all that apply

☑ Direct operations

(2.5.1.4) Actions and procedures to minimize adverse impacts

Select all that apply

☑ Upgrading of process equipment/methods

☑ Beyond compliance with regulatory requirements

☑ Reduction or phase out of hazardous substances

☑ Provision of best practice instructions on product use

☑ Requirement for suppliers to comply with regulatory requirements

☑ Industrial and chemical accidents prevention, preparedness, and response

(2.5.1.5) Please explain

We strive to minimize potential impacts from these solvents and synthetic organic compounds by segregating and managing these regulated waste products at offsite disposal facilities. In our synthetic organic compound processing operations, we employ stringent chemical hygiene and cleaning practices to minimize potential releases to the environment.

Row 4

(2.5.1.1) Water pollutant category

Select from:

☑ Other nutrients and oxygen demanding pollutants

(2.5.1.2) Description of water pollutant and potential impacts

Wastewater that is not properly treated has the potential to harm human health and the natural environment. All our facilities are expected to maintain the necessary compliance required by their local regulatory authorities in their respective geographical location. Amgen characterizes and quantifies oxygen demanding pollutants and other nutrients at our manufacturing facilities. At some of our larger manufacturing sites,, such as Singapore, Puerto Rico, and Rhode Island, we pretreat oxygen-demanding pollutants in our onsite biological wastewater treatment systems. Across the network, we discharge to a municipal wastewater treatment plant or at a permitted outfall.

(2.5.1.3) Value chain stage

Select all that apply

☑ Direct operations

(2.5.1.4) Actions and procedures to minimize adverse impacts

Select all that apply

☑ Beyond compliance with regulatory requirements

☑ Industrial and chemical accidents prevention, preparedness, and response

☑ Discharge treatment using sector-specific processes to ensure compliance with regulatory requirements

(2.5.1.5) Please explain

Amgen characterizes and quantifies oxygen-demanding pollutants and other nutrients at our manufacturing facilities. At some of our larger manufacturing sites such as Singapore, Puerto Rico, and Rhode Island, we pretreat oxygen-demanding pollutants in our onsite biological wastewater treatment systems.

Row 5

(2.5.1.1) Water pollutant category

Select from:

☑ Oil

(2.5.1.2) Description of water pollutant and potential impacts

Wastewater that is not properly treated has the potential to harm human health and the natural environment. All our facilities are expected to maintain the necessary compliance required by their local regulatory authorities in their respective geographical location. Amgen identifies and characterizes our oil-containing waste streams within our utility systems, equipment, and onsite cafeteria operations. We design our facilities with hazardous material spill prevention controls such as secondary containment, oil water separators, and stormwater filtration devices. Where applicable, we develop and implement Spill Prevention Control and Countermeasure Plans and Storm Water Pollution Prevention Plans.

(2.5.1.3) Value chain stage

Select all that apply

☑ Direct operations

(2.5.1.4) Actions and procedures to minimize adverse impacts

Select all that apply

☑ Assessment of critical infrastructure and storage condition (leakages, spillages, pipe erosion etc.) and their resilience

☑ Beyond compliance with regulatory requirements

☑ Industrial and chemical accidents prevention, preparedness, and response

(2.5.1.5) Please explain

Amgen identifies and characterizes our oil-containing waste streams within our utility systems, equipment, and our onsite cafeteria operations. We design our facilities with hazardous material spill prevention controls such as secondary containment, oil water separators, and storm water filtration devices. Where applicable, we develop and implement Spill Prevention Control and Countermeasure Plans and Storm Water Pollution Prevention Plans.
[Add row]

C3. Disclosure of risks and opportunities

(3.1) Have you identified any environmental risks which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future?

Climate change

(3.1.1) Environmental risks identified

Select from:

☑ Yes, both in direct operations and upstream/downstream value chain

Water

(3.1.1) Environmental risks identified

Select from:

☑ Yes, both in direct operations and upstream/downstream value chain

Plastics

(3.1.1) Environmental risks identified

Select from:

☑ No

(3.1.2) Primary reason why your organization does not consider itself to have environmental risks in your direct operations and/or upstream/downstream value chain

Select from:

☑ Evaluation in progress

(3.1.3) Please explain

Amgen is currently in a multi-year process of expanding its risk and scenario analysis scopes to include a review of plastics. We have not yet completed our evaluation of Amgen's use of plastics across our value chain.
[Fixed row]

(3.1.1) Provide details of the environmental risks identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future.

Climate change

(3.1.1.1) Risk identifier

Select from:
☑ Risk1

(3.1.1.3) Risk types and primary environmental risk driver

Acute physical
☑ Cyclone, hurricane, typhoon

(3.1.1.4) Value chain stage where the risk occurs

Select from:
☑ Direct operations

(3.1.1.6) Country/area where the risk occurs

Select all that apply
☑ Puerto Rico

(3.1.1.9) Organization-specific description of risk

Situation: Increased severity and frequency of extreme weather events could affect our Puerto Rico site. Puerto Rico was affected by droughts in mid-2010s and Hurricane Maria in 2017. The critical areas of our manufacturing facilities were not significantly affected by Maria or recent storms. However, electrical service restoration on the island was slow, and our facility operated with electrical power from backup generators until the grid was restored. Task: In 2023, Amgen performed a wide-ranging risk assessment to further our understanding of climate-related physical and transition risks across our value chain, under multiple scenarios and timeframes. Action: The work included an assessment of climate-related risk at our Puerto Rico site. Results: The scenario analysis revealed the possibility of storm-related precipitation and wildfire as physical climate hazards under each scenario until 2030. Multiple engineering mitigation measures have been established or enhanced to reduce or partially mitigate such risks, including a combined heat and power plant, back-up generators, and an on-site wastewater treatment plant enabling water reuse for industrial purposes. We are looking at the feasibility of different renewable energy projects to reduce reliance on the municipal grid and reduce emissions. We will continue to evaluate and implement engineering improvements to prepare for potential increases in extreme weather events and new physical climate risks in the longer term.

(3.1.1.11) Primary financial effect of the risk

Select from:

☑ Disruption in production capacity

(3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☑ Short-term

(3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

Select from:

☑ About as likely as not

(3.1.1.14) Magnitude

Select from:

☑ Medium

(3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

Physical climate-related impacts at our Puerto Rico facility has the potential to disrupt our supply of medicines to patients, although we have not as of yet experienced such disruption.

(3.1.1.17) Are you able to quantify the financial effect of the risk?

Select from:

☑ Yes

(3.1.1.19) Anticipated financial effect figure in the short-term – minimum (currency)

500000

(3.1.1.20) Anticipated financial effect figure in the short-term – maximum (currency)

20000000

(3.1.1.25) Explanation of financial effect figure

Based on Amgen's risk impact criteria, the minimum financial impact figure is <$500K and the maximum figure is >$20M. These values are evaluated every year by Amgen's Strategic Planning and Risk group within the Operations organization. The risk-assessment process breaks down major risks (e.g., hurricanes, earthquakes, fires) into specific sub-risk areas.

(3.1.1.26) Primary response to risk

Compliance, monitoring and targets

☑ Implementation of environmental best practices in direct operations

(3.1.1.27) Cost of response to risk

545000

(3.1.1.28) Explanation of cost calculation

$545,000 represents the approximate cost of the 2023 external consulting fees for climate risk work. Other recent engineering improvements at this site have been implemented, at a cost of over $54,000,000. The improvements were driven by wider strategic planning and increased capacity needs, but included climate-related efficiencies, redundancies, and resilience considerations.

(3.1.1.29) Description of response

Environmental risks, including potential risks from climate change, are considered at a functional level within Global Engineering; Environment, Health & Safety; and the Operational Strategy and Business Resilience teams, and at a site level within our operating sites. Various functions within the operating sites make up a larger risk community within Amgen that elevates enterprise level risks for consideration in connection with the Amgen Enterprise Risk Management (ERM) process. Enterprise-level risks are compared cross-functionally and organized into an executive-level profile for reporting purposes. Amgen partners with our global insurance broker who advises on corporate insurance companies that provide capital loss and business continuity insurance to support Amgen's insurance program in managing enterprise risk. As part of the insurance package, facility-specific environmental hazards are assessed. Building designs incorporate mitigation measures to reduce associated risks. At the Puerto Rico facility, multiple engineering mitigation measures have been established or enhanced to reduce such risk. The site operates a combined heat and power plant and has back-up power generators for operational continuity. We also upgraded generator controls to improve robustness of automated operation. Roof membranes have been upgraded on critical buildings. The site also has an on-site wastewater treatment plant that treats and reuses water for industrial purposes, reducing reliance on municipal water, for example during an emergency. Additional freezer warehouses have also been added to the site. Amgen is also looking at the feasibility of different renewable energy projects to reduce reliance on the municipal grid and reduce greenhouse gas emissions. Amgen will continue to evaluate and implement additional engineering improvements to prepare for potential increases in extreme weather events and new physical climate risks, such as extreme weather events in the longer term.

Water

(3.1.1.1) Risk identifier

Select from:

☑ Risk1

(3.1.1.3) Risk types and primary environmental risk driver

Acute physical

☑ Drought

(3.1.1.4) Value chain stage where the risk occurs

Select from:

☑ Direct operations

(3.1.1.6) Country/area where the risk occurs

Select all that apply

☑ United States of America

(3.1.1.7) River basin where the risk occurs

Select all that apply

☑ Other, please specify :North Pacific

(3.1.1.9) Organization-specific description of risk

Situation: Amgen operates key R&D, manufacturing, and product warehouse operations in Thousand Oaks, California, a region prone to drought with the potential for water usage restrictions. Furthermore, prolonged drought increases the associated seasonal wildfire risk. A substantial disruption in our ability to operate this manufacturing facility through restricted water supply could significantly and adversely affect our ability to supply our product candidates for use in our clinical trials, leading to delays in the development of our product candidates. Temperature increases and lack of rainfall can exacerbate drought conditions that could extend the wildfire season and increase the likelihood and severity of a fire event. Past wildfire incidents have occurred in areas near our operations that have disrupted normal business operations for very short periods.

(3.1.1.11) Primary financial effect of the risk

Select from:

☑ Disruption in production capacity

(3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☑ Medium-term

(3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

Select from:

☑ About as likely as not

(3.1.1.14) Magnitude

Select from:

☑ Medium

(3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

Physical climate-related impacts at our Thousand Oaks facility may disrupt our supply of medicines to patients.

(3.1.1.17) Are you able to quantify the financial effect of the risk?

Select from:

☑ Yes

(3.1.1.21) Anticipated financial effect figure in the medium-term – minimum (currency)

1000000

(3.1.1.22) Anticipated financial effect figure in the medium-term – maximum (currency)

20000000

(3.1.1.25) Explanation of financial effect figure

Based on Amgen's risk impact criteria, the minimum financial impact figure is <$500K and the maximum figure is >$20M. These values are evaluated every year by Amgen's Strategic Planning and Risk group within the Operations organization. The risk assessment process breaks down major risks into specific sub-risks for each.

(3.1.1.26) Primary response to risk

Compliance, monitoring and targets

☑ Implementation of environmental best practices in direct operations

(3.1.1.27) Cost of response to risk

545000

(3.1.1.28) Explanation of cost calculation

$545,000 represents the approximate cost of the 2023 external consulting fees for climate risk work that considered this risk.

(3.1.1.29) Description of response

In 2020, Amgen set a goal to reduce water consumption by 40% from a 2019 baseline by 2027. This reduction target is incremental to previous water reductions of approximately 30% between 2007 and 2019. In 2023, Amgen performed a wide-ranging risk assessment to further our understanding of climate-related physical risks and transition risks across our value chain under multiple risk scenarios and across short-, medium-, and long-term timeframes (to 2050). The 2023 work included a broad-scale assessment of climate-related risk at Amgen's Thousand Oaks, California, facility. Water scarcity and wildfire risks are short-term physical climate risks at that facility. To reduce the risk associated with water scarcity, Amgen has implemented multiple measures; for example, Amgen Thousand Oaks has executed sustainability projects to implement improved reverse osmosis technologies, manufacturing process improvements such as clean-in-place (CIP) cycles, campus improvements such as low-flow fixtures across administrative spaces, and drought-friendly landscaping to reduce water consumption. Amgen is in the design phase of a campus-wide project to treat and reuse cooling tower blowdown and reverse osmosis reject wastewater to increase the use of recycled water. The site also developed a Wildfire/Red Flag Warning/Severe Weather playbook for actions before, during, and after an event. In 2024, Amgen achieved a cumulative 488,000 cubic meters (CM) of water savings through the execution of sustainability projects across the enterprise. Amgen applies an internal price of water of $80 per CM as an investment evaluator. Based on historical projects, we determined that $80 per CM reduced is required to drive innovation and efficiency into internal projects. We evaluate water reduction projects and initiatives for each of our major locations and assess opportunities.

Climate change

(3.1.1.1) Risk identifier

Select from:

☑ Risk2

(3.1.1.3) Risk types and primary environmental risk driver

Acute physical

☑ Wildfires

(3.1.1.4) Value chain stage where the risk occurs

Select from:

☑ Direct operations

(3.1.1.6) Country/area where the risk occurs

Select all that apply

☑ United States of America

(3.1.1.9) Organization-specific description of risk

Situation: Amgen operates R&D, manufacturing and warehouse operations in Thousand Oaks, California, and this location is vulnerable to wildfire risk. A substantial disruption in our ability to operate this manufacturing facility could affect the ability to supply product candidates for use in clinical trials, causing delays in the development of product candidates. Temperature increases and lack of rainfall can exacerbate drought conditions that could extend the wildfire season and increase the likelihood and severity of a fire event. Amgen has taken several precautions to limit operational wildfire impacts; for example, site buildings are constructed with cement walls and fire-resistant roofs. Past wildfire incidents have occurred near our operations that disrupted normal business operations for very short periods. Task: In 2023, Amgen performed a wide-ranging risk assessment to further our understanding of climate-related physical and transition risks across our value chain under multiple risk scenarios across short-, medium- and long-term timeframes. Action: The 2023 risk assessment included an evaluation of risk at Amgen's Thousand Oaks facility. Results: Wildfires and water scarcity are short-term risks. Multiple engineering and disaster prevention measures are in place that reduce water reliance, for example improved reverse osmosis technologies, manufacturing process improvements such as clean-in-place (CIP) cycles, and landscape improvements.

(3.1.1.11) Primary financial effect of the risk

Select from:

☑ Disruption in production capacity

(3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☑ Short-term

(3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

Select from:

☑ About as likely as not

(3.1.1.14) Magnitude

Select from:

☑ Medium

(3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

Physical climate-related impacts at our Thousand Oaks facility may disrupt our supply of medicines to patients.

(3.1.1.17) Are you able to quantify the financial effect of the risk?

Select from:

☑ Yes

(3.1.1.19) Anticipated financial effect figure in the short-term – minimum (currency)

500000

(3.1.1.20) Anticipated financial effect figure in the short-term – maximum (currency)

20000000

(3.1.1.25) Explanation of financial effect figure

Based on Amgen's risk impact criteria, the minimum financial impact figure is <$500K and the maximum figure is >$20M. These values are evaluated every year by Amgen's Strategic Planning and Risk group within the Operations organization. The risk assessment process breaks down major risks into specific sub-risks for each.

(3.1.1.26) Primary response to risk

Compliance, monitoring and targets

☑ Implementation of environmental best practices in direct operations

(3.1.1.27) Cost of response to risk

545000

(3.1.1.28) Explanation of cost calculation

$545,000 represents the approximate cost of the 2023 external consulting fees for climate risk work.

(3.1.1.29) Description of response

Environmental risks, including the potential risks from climate change, are considered at a functional level within Global Engineering; Environment, Health & Safety; and the Operational Strategy and Business Resilience teams, and at a site level within our operating sites. Various functions with the operating sites make up a larger risk community within Amgen that elevates enterprise-level risks for consideration in connection with the Amgen Enterprise Risk Management (ERM) process. Amgen partners with our global insurance broker who advises on corporate insurance companies that provide capital loss and business continuity insurance to support Amgen's insurance program in managing enterprise risk. As part of the insurance package, facility-specific environmental hazards are assessed. Multiple engineering and disaster prevention measures are in place at Amgen's Thousand Oaks facility that significantly reduce wildfire risks. To reduce the risk associated with water scarcity, Amgen has already implemented multiple measures, including, for example, innovative improved reverse osmosis technologies that significantly reduce water loss from high-purity water generation, manufacturing process improvements such as clean-in-place (CIP) cycles that significantly reduce water consumption, and landscape improvements to significantly reduce water consumption. Amgen is in the design phase of a campus-wide project to treat and reuse cooling tower blowdown and reverse osmosis reject sanitary wastewater to reduce water needs. The site also developed a Wildfire/Red Flag Warning/Severe Weather playbook for actions before, during, and after an event. Plans are reviewed, exercised periodically, and have been utilized in actual events. Backup generators are available, and hitching posts are installed for all critical buildings. Fuel is stored onsite and is expected to be sufficient for more than two days of operations, and Amgen has a local guaranteed refueling contract.

Climate change

(3.1.1.1) Risk identifier

Select from:

☑ Risk3

(3.1.1.3) Risk types and primary environmental risk driver

Acute physical

☑ Other acute physical risk, please specify :Acute physical - Cyclone, hurricane, typhoon; Flood (coastal, fluvial, pluvial, groundwater); Heavy precipitation (rain, hail, snow/ice); Storm (including blizzards, dust, and sandstorms); Tornado; Wildfire

(3.1.1.4) Value chain stage where the risk occurs

Select from:

☑ Upstream value chain

(3.1.1.6) Country/area where the risk occurs

Select all that apply

☑ Canada
☑ Ireland
☑ Singapore
☑ Netherlands
☑ Puerto Rico
☑ United States of America
☑ United Kingdom of Great Britain and Northern Ireland

(3.1.1.9) Organization-specific description of risk

Situation: Amgen relies on external supply chains for business-critical materials, including certain raw materials, medical devices and components necessary for the manufacturing of our commercial and clinical products. There is a potential for disruption within our global supply chain due to extreme weather events. Our suppliers, vendors, and business partners face similar risks as described in Risk 1 and Risk 2. Task: In 2023, Amgen performed a wide-ranging risk assessment to further our understanding of climate-related physical and transition risks across our value chain under multiple risk scenarios across short-, medium-, and long-term timeframes. Action: The 2023 work included an assessment of risk at key supplier sites with global representation. Results: Wind, precipitation, and wildfire were identified as short-term risks, with a potential for supply chain impacts and interruptions.

(3.1.1.11) Primary financial effect of the risk

Select from:

☑ Disruption in upstream value chain

(3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☑ Short-term

(3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

Select from:

☑ About as likely as not

(3.1.1.14) Magnitude

Select from:

☑ Low

(3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

Increase operational costs, through suppliers' increased costs of operation being passed on to Amgen.

(3.1.1.17) Are you able to quantify the financial effect of the risk?

Select from:

☑ Yes

(3.1.1.19) Anticipated financial effect figure in the short-term – minimum (currency)

500000

(3.1.1.20) Anticipated financial effect figure in the short-term – maximum (currency)

20000000

(3.1.1.25) Explanation of financial effect figure

Based on Amgen's risk impact criteria, the minimum financial impact figure is <$500K and the maximum figure is >$20M. These figures depend on the number and importance of external suppliers negatively impacted by severe weather in a given year.

(3.1.1.26) Primary response to risk

Engagement

☑ Other engagement, please specify :Amgen worked with an external consultant in 2023 to perform scenario analysis and subsequent climate risk assessments for prioritized sites, including six supplier sites. The 2024 scenario analysis and climate risk assessments were site-based.

(3.1.1.27) Cost of response to risk

545000

(3.1.1.28) Explanation of cost calculation

$545,000 represents the approximate cost of the 2023 external consulting fees for climate risk work.

(3.1.1.29) Description of response

Environmental risks, including the potential risks from climate change, are considered at a functional level within Global Engineering; Environment, Health & Safety; and the Operational Strategy and Business Resilience teams, and at a site level within our operating sites. The scope of risk management activities covers Amgen operations and supplier sites. Amgen has multiple mitigation and redundancy measures in place to prevent supply chain disruptions. For example, Amgen has detailed business continuity plans, limits sole-source suppliers, and selects suppliers located in different regions to mitigate the risk of supply disruptions. Each supplier is also expected to have a business continuity plan that includes risk mitigation in the event of extreme weather events or other disruptions.

Climate change

(3.1.1.1) Risk identifier

Select from:

☑ Risk4

(3.1.1.3) Risk types and primary environmental risk driver

Policy

☑ Carbon pricing mechanisms

(3.1.1.4) Value chain stage where the risk occurs

Select from:

☑ Upstream value chain

(3.1.1.6) Country/area where the risk occurs

Select all that apply

☑ Canada

☑ Ireland

☑ Singapore

☑ Netherlands

☑ United States of America

☑ United Kingdom of Great Britain and Northern Ireland

☑ Puerto Rico

(3.1.1.9) Organization-specific description of risk

Situation: Increases in supplier product prices due to carbon tax increases might be short-, medium- and long-term risks for our business. Task: In 2023, Amgen performed scenario analysis to better understand transition climate risk across short-, medium- and long-term timeframes. The potential increase in carbon taxes globally was identified as a regulatory transition risk. Action: Three transition risk climate scenarios were employed to determine value chain risks associated with carbon taxes in the short-term. Results: The scenario analysis revealed that carbon taxes are likely to increase by 2030 in every scenario, though at different rates and with divergent policies across countries and scenarios. Raw materials, contract manufacturers, construction, and device supplier categories are believed to be most at risk if carbon prices increase. Amgen is and will continue to engage with our suppliers on their decarbonization efforts to mitigate this risk

(3.1.1.11) Primary financial effect of the risk

Select from:

☑ Increased indirect [operating] costs

(3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☑ Short-term

(3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

Select from:

☑ About as likely as not

(3.1.1.14) Magnitude

Select from:

☑ Medium

(3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

Increase operational costs, through supplier's increased costs of operation being passed on to Amgen.

(3.1.1.17) Are you able to quantify the financial effect of the risk?

Select from:

☑ No

(3.1.1.26) Primary response to risk

Engagement

☑ Other engagement, please specify :Amgen worked with an external consultant in 2023 to perform scenario analysis and transition risk financial quantification. In 2024, consulting work focused mostly on priority site assessments.

(3.1.1.27) Cost of response to risk

1045000

(3.1.1.28) Explanation of cost calculation

$1,045,000 represents the approximate cost of the 2023 and 2024 external consulting fees for climate risk work that considered this risk.

(3.1.1.29) Description of response

Environmental risks, including those potential risks from climate change, are considered at a functional level within Global Engineering; Environment, Health & Safety; and the Operational Strategy and Business Resilience teams, and at a site level within our operating sites. Enterprise-level risks are compared cross functionally and organized into an executive-level profile for reporting purposes. Amgen continues to reduce its own emissions through innovation and efficiency. Across our value chain, Amgen continues to engage with our suppliers on their own decarbonization efforts to mitigate carbon tax risk. As part of our 2027 environmental sustainability plan, in 2022, we established a Scope 3 supplier engagement target to engage with 73% of our suppliers by spend in key categories to support their adoption of science-based carbon emission reduction targets. These key suppliers represent approximately 67% of our Scope 3 emissions from a 2019 baseline. In 2024, Amgen achieved our 73% supplier engagement target as a preliminary matter; we intend to maintain or exceed this level of supplier commitment in accordance with our SBTi target through 2027, as our suppliers may change. Amgen is a sponsor of the global pharmaceuticals industry Energize Program, aimed at accelerating adoption of renewable energy and reducing GHG emissions among suppliers. This first-of-its-kind industry program will train pharmaceutical suppliers on renewable energy adoption and increase access to renewable energy sourcing. This gives suppliers – who may not otherwise have the internal resources or expertise available – the opportunity to participate in the market for power purchase agreements (PPAs).

Climate change

(3.1.1.1) Risk identifier

Select from:

☑ Risk5

(3.1.1.3) Risk types and primary environmental risk driver

Technology

☑ Transition to lower emissions technology and products

(3.1.1.4) Value chain stage where the risk occurs

Select from:

☑ Direct operations

(3.1.1.6) Country/area where the risk occurs

Select all that apply

☑ Canada

☑ Ireland

☑ Singapore

☑ Netherlands

☑ Puerto Rico

☑ United States of America

☑ United Kingdom of Great Britain and Northern Ireland

(3.1.1.9) Organization-specific description of risk

Situation: Amgen seeks alternatives to fossil fuels to power operations to reduce scope 1 emissions. Where alternatives to fossil fuels are not available in the short-term, we are moving to cleaner-burning fossil fuels to reduce our carbon footprint. Renewable alternatives are becoming increasingly available, but they are still in limited supply at capacities necessary for bioprocess manufacturing operations. At the same time, the price of natural gas is projected to continue to increase in the short-term. Task: Amgen performed a scenario analysis to better understand transition risks across short-, medium- and long-term timeframes (to 2050). The potential increase in the cost of natural gas globally was identified as a technology transition risk. Action: Three transition risk climate scenarios were employed to project natural gas prices. Results: Amgen is factoring in these projected increases in natural gas costs as it continues to develop its roadmap for decarbonization and electrification.

(3.1.1.11) Primary financial effect of the risk

Select from:

☑ Increased direct costs

(3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☑ Short-term

☑ Medium-term

☑ Long-term

(3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

Select from:

☑ About as likely as not

(3.1.1.14) Magnitude

Select from:

☑ Medium-high

(3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

Increase operational costs, through higher natural gas costs.

(3.1.1.17) Are you able to quantify the financial effect of the risk?

Select from:

☑ No

(3.1.1.26) Primary response to risk

Engagement

☑ Other engagement, please specify :Amgen worked with an external consultant in 2023 to perform scenario analysis and transition risk financial quantification and has set a SBTi-approved carbon emissions Scope 1 and 2 target.

(3.1.1.27) Cost of response to risk

1045000

(3.1.1.28) Explanation of cost calculation

$1,045,000 represents the approximate cost of the 2023 and 2024 external consulting fees for climate risk work that considered this risk.

(3.1.1.29) Description of response

Amgen is implementing multiple measures across its own operations and its supply chain to reduce fossil-fuel-derived natural gas needs. In 2024, $22.8 million in capital expenditure was allocated for carbon reduction projects. Our new Ohio facility was designed to be fully electrified and seeks to eliminate reliance on natural gas. More generally, Amgen uses two forms of an internal price on carbon (IPoC) to encourage the design and implementation of projects that reduce energy use and carbon emissions. The first is an Investment Evaluator used by our Investment Lifecycle Management process to evaluate the purchase of innovative and efficient equipment that supports further reductions in carbon. For this evaluation, we apply an internal price of carbon of $1,600 USD per metric ton (MT) of carbon dioxide equivalent (CO2e) emissions. The second form is an Internal Fee. All Amgen capital projects over $500K require a sustainability estimate of impact, including impact for carbon. For projects that result in an increase in CO2e emissions by greater than 500 metric tons, we apply an internal fee of $1,000 USD per metric ton. Proceeds from the internal carbon fee are then added to our overall environmental sustainability budget to fund additional reduction projects. Beyond direct operations, Amgen is engaging and will continue to engage with our suppliers on their decarbonization efforts to mitigate the risk associated with increased carbon taxes. Amgen is factoring in projected increases in natural gas costs as it continues to develop its roadmap for decarbonization and electrification.

Climate change

(3.1.1.1) Risk identifier

Select from:

☑ Risk6

(3.1.1.3) Risk types and primary environmental risk driver

Technology

☑ Other technology risk, please specify :Availability of renewable energy

(3.1.1.4) Value chain stage where the risk occurs

Select from:

☑ Direct operations

(3.1.1.6) Country/area where the risk occurs

Select all that apply

☑ China
☑ Egypt
☑ India
☑ Italy
☑ Japan
☑ Israel
☑ Mexico
☑ Norway
☑ Poland
☑ Sweden
☑ Denmark
☑ Finland
☑ Germany
☑ Hungary
☑ Iceland
☑ Malaysia
☑ Portugal
☑ Slovakia
☑ Slovenia
☑ Thailand
☑ Spain
☑ Brazil
☑ Canada
☑ France
☑ Greece
☑ Turkey
☑ Austria
☑ Belgium
☑ Croatia
☑ Czechia
☑ Ireland
☑ Morocco
☑ Romania
☑ Bulgaria
☑ Colombia
☑ Argentina
☑ Australia
☑ Lithuania
☑ Singapore
☑ Netherlands

☑ Philippines
☑ Puerto Rico
☑ Switzerland
☑ Saudi Arabia
☑ South Africa
☑ United Kingdom of Great Britain and Northern Ireland
☑ Taiwan, China
☑ Republic of Korea
☑ Russian Federation
☑ United Arab Emirates
☑ United States of America

(3.1.1.9) Organization-specific description of risk

Situation: Amgen has SBTi-approved targets that include aspirations to increase our annual sourcing of renewable electricity from 29% in 2019 to 100% by 2027, and to then annually source 100% renewable electricity through 2030. Amgen is continually seeking alternatives to fossil fuels to power operations to reduce scope 1 emissions, including for example, through electrification. The availability of clean, renewable electricity varies across countries and markets. Task: Amgen performed scenario analysis to better understand transition climate risks across short-, medium-, and long-term timeframes. The availability of clean, renewable electricity was identified as a technology transition risk. Action: Amgen performed scenario analysis and modeled renewable, clean electricity availability under different scenarios. We considered three transition risk climate scenarios to project renewable electricity globally across different time horizons. Results: Amgen is factoring in associated projections to secure clean, renewable electricity in the market as these alternatives become available.

(3.1.1.11) Primary financial effect of the risk

Select from:
☑ Increased direct costs

(3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply
☑ Short-term
☑ Medium-term
☑ Long-term

(3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

Select from:
☑ About as likely as not

(3.1.1.14) Magnitude

Select from:

☑ Medium-high

(3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

Increase operational costs due to low availability of renewable electricity driving increased prices.

(3.1.1.17) Are you able to quantify the financial effect of the risk?

Select from:

☑ No

(3.1.1.26) Primary response to risk

Compliance, monitoring and targets

☑ Other compliance, monitoring or target, please specify :Amgen worked with an external consultant in 2023 to perform scenario analysis and transition risk financial quantification.

(3.1.1.27) Cost of response to risk

1045000

(3.1.1.28) Explanation of cost calculation

$1,045,000 represents the approximate cost of the 2023 and 2024 external consulting fees for climate risk work that considered this risk.

(3.1.1.29) Description of response

Amgen's first focus is to minimize energy requirements, through innovative approaches, processes, and efficiency improvements. Next, Amgen factors in global electricity projections to secure clean, renewable electricity in the market as these alternatives become available. At the end of 2024, renewable electricity accounted for more than 90% of our total purchased electricity consumption. Additionally, we have installed on-site solar projects at our Singapore, Netherlands, Ohio,

and North Carolina facilities. In 2024, we also participated in or sponsored environmental sustainability programs and initiatives to educate suppliers on renewable energy procurement, responsible sourcing, and climate strategies, including setting science-based targets. These programs and initiatives include Energize, the Pharmaceutical Supply Chain Initiative, the Responsible Health Initiative, and My Green Lab's initiative Converge, which helps pharmaceutical suppliers set science-based targets.

Water

(3.1.1.1) Risk identifier

Select from:

☑ Risk2

(3.1.1.3) Risk types and primary environmental risk driver

Acute physical

☑ Cyclone, hurricane, typhoon

(3.1.1.4) Value chain stage where the risk occurs

Select from:

☑ Direct operations

(3.1.1.6) Country/area where the risk occurs

Select all that apply

☑ Puerto Rico

(3.1.1.7) River basin where the risk occurs

Select all that apply

☑ Other, please specify :Rio Grande de Loíza

(3.1.1.9) Organization-specific description of risk

An increased severity and frequency of extreme weather events could affect our manufacturing sites, potentially causing a reduction or disruption in production capacity. Puerto Rico was affected by droughts in the mid-2010s and by Hurricane Maria in 2017. These natural disasters may continue to affect properties and the electric grid and communications networks. The critical areas of our commercial manufacturing facilities were not significantly affected by Maria (nor by recent storms). However, electrical service restoration on the island was slow, and our facility operated with electrical power from backup generators until the grid was restored. Further instability of the electric grid could require us to increase generator use.

(3.1.1.11) Primary financial effect of the risk

Select from:

☑ Disruption in production capacity

(3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☑ Short-term

(3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

Select from:

☑ About as likely as not

(3.1.1.14) Magnitude

Select from:

☑ Medium

(3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

Physical climate-related impacts at our Puerto Rico facility may disrupt our supply of medicines to patients.

(3.1.1.17) Are you able to quantify the financial effect of the risk?

Select from:

☑ Yes

(3.1.1.19) Anticipated financial effect figure in the short-term – minimum (currency)

1000000

(3.1.1.20) Anticipated financial effect figure in the short-term – maximum (currency)

20000000

(3.1.1.25) Explanation of financial effect figure

These risk impact ranges are the standards for Amgen for these types of risk assessments. The risk assessment process breaks down major risks like hurricanes, earthquakes, and fires into specific sub-risks for each type.

(3.1.1.26) Primary response to risk

Compliance, monitoring and targets

☑ Implementation of environmental best practices in direct operations

(3.1.1.27) Cost of response to risk

545000

(3.1.1.28) Explanation of cost calculation

$545,000 represents the approximate cost of the 2023 external consulting fees for climate risk work that considered this risk.

(3.1.1.29) Description of response

Amgen has taken several precautions to limit the impacts of storm events. Amgen manufacturing sites have redundant power generation sources in the event that severe weather halts operations. Amgen also maintains contracts for fuel replenishment for additional power generators to continue operations. Furthermore, Amgen's Puerto Rico facility operates a highly efficient cogeneration plant to increase redundancy. In 2022, Amgen performed a risk assessment project to improve its understanding of acute climate-related physical risks, including risks to our Puerto Rico site. Hazards were considered across short-, medium-, and long-term timeframes, using scenario RCP 4.5. In 2023, Amgen performed a wide-ranging risk assessment to improve its understanding of acute and chronic climate-related physical and transition risks across our value chain under three scenarios to 2050. The 2023 wide-ranging scenario included a broad-scale assessment of climate-related risks at Amgen's Puerto Rico facility, including acute and chronic risks across multiple timeframes. Results: The scenario analysis revealed storm-related precipitation and wildfire as the highest physical climate hazards under each scenario in the short-term risk (to 2030). Multiple engineering mitigation measures

already exist at the Puerto Rico facility to reduce water-related risks. For example, the site operates a combined heat and power plant and has emergency power generators for continuity of operations during an extreme weather event. Further, the site also has an on-site wastewater treatment plant that treats and reuses water for industrial purposes, reducing reliance on municipal water, during an emergency. Two additional on-site water wells were constructed to increase capacity during low water supply periods. Amgen will continue to evaluate and implement engineering improvements to prepare for potential increases in extreme weather events and new physical climate risks in the longer term.

Water

(3.1.1.1) Risk identifier

Select from:

☑ Risk3

(3.1.1.3) Risk types and primary environmental risk driver

Acute physical

☑ Other acute physical risk, please specify :Acute physical - Cyclone, hurricane, typhoon; Flood (coastal, fluvial, pluvial, groundwater); Heavy precipitation (rain, hail, snow/ice); Storm (including blizzards, dust, and sandstorms); Tornado; Wildfire

(3.1.1.4) Value chain stage where the risk occurs

Select from:

☑ Upstream value chain

(3.1.1.6) Country/area where the risk occurs

Select all that apply

☑ Canada
☑ Ireland
☑ Singapore
☑ Netherlands
☑ Puerto Rico
☑ United States of America
☑ United Kingdom of Great Britain and Northern Ireland

(3.1.1.7) River basin where the risk occurs

Select all that apply

☑ Fraser River

☑ Mississippi River

☑ Other, please specify :North Atlantic, North Pacific, Rio Grande de Loiza PR, Ohio River Basin

(3.1.1.9) Organization-specific description of risk

Situation: Amgen relies on external supply chains for business-critical materials, including certain raw materials, medical devices, and components necessary for the manufacturing of our commercial and clinical products. There is a potential for disruption within our global supply chain due to extreme weather events. Our suppliers, vendors and business partners face similar risks as described in Risk 1 and Risk 2. Task: In 2023, Amgen performed a wide-ranging risk assessment to further our understanding of climate-related physical and transition risks across our value chain under multiple risk scenarios across short-, medium-, and long-term timeframes. Action: The 2023 work included an assessment of risk at key supplier sites with global representation. Results: Wind, precipitation, and wildfire were identified as short-term risks with a potential for supply chain impacts and interruptions.

(3.1.1.11) Primary financial effect of the risk

Select from:

☑ Disruption in upstream value chain

(3.1.1.12) Time horizon over which the risk is anticipated to have a substantive effect on the organization

Select all that apply

☑ Short-term

(3.1.1.13) Likelihood of the risk having an effect within the anticipated time horizon

Select from:

☑ About as likely as not

(3.1.1.14) Magnitude

Select from:

☑ Low

(3.1.1.16) Anticipated effect of the risk on the financial position, financial performance and cash flows of the organization in the selected future time horizons

Increase operational costs, through suppliers' increased costs of operation being passed on to Amgen.

(3.1.1.17) Are you able to quantify the financial effect of the risk?

Select from:

☑ Yes

(3.1.1.19) Anticipated financial effect figure in the short-term – minimum (currency)

500000

(3.1.1.20) Anticipated financial effect figure in the short-term – maximum (currency)

20000000

(3.1.1.25) Explanation of financial effect figure

Based on Amgen's risk impact criteria, the minimum financial impact figure is <$500K and the maximum figure is >$20M. These figures depend on the number and importance of external suppliers negatively impacted by severe weather in a given year.

(3.1.1.26) Primary response to risk

Engagement

☑ Other engagement, please specify :Amgen worked with an external consultant in 2023 to perform scenario analysis and subsequent climate risk assessments for prioritized sites, including six supplier sites. The 2024 scenario analysis and climate risk assessments were site-based.

(3.1.1.27) Cost of response to risk

545000

(3.1.1.28) Explanation of cost calculation

$545,000 represents the approximate cost of the 2023 external consulting fees for climate risk work.

(3.1.1.29) Description of response

Environmental risks, including the potential risks from climate change, are considered at a functional level within Global Engineering; Environment, Health & Safety; and the Operational Strategy and Business Resilience teams, and at a site level within our operating sites. The scope of risk management activities covers Amgen operations and supplier sites. Amgen has multiple mitigation and redundancy measures in place to prevent supply chain disruptions. For example, Amgen has detailed business continuity plans, limits sole-source suppliers, and selects suppliers located in different regions to mitigate the risk of supply disruptions. Each supplier is also expected to have a business continuity plan that includes risk mitigation in the event of extreme weather events or other disruptions.
[Add row]

(3.1.2) Provide the amount and proportion of your financial metrics from the reporting year that are vulnerable to the substantive effects of environmental risks.

Climate change

(3.1.2.1) Financial metric

Select from:
☑ Revenue

(3.1.2.7) Explanation of financial figures

These values are considered confidential at this time.

Water

(3.1.2.1) Financial metric

Select from:
☑ Revenue

(3.1.2.7) Explanation of financial figures

These values are considered confidential at this time.

[Add row]

(3.2) Within each river basin, how many facilities are exposed to substantive effects of water-related risks, and what percentage of your total number of facilities does this represent?

Row 1

(3.2.1) Country/Area & River basin

Puerto Rico

☑ Other, please specify :Rio Grande de Loíza

(3.2.2) Value chain stages where facilities at risk have been identified in this river basin

Select all that apply

☑ Direct operations

(3.2.3) Number of facilities within direct operations exposed to water-related risk in this river basin

1

(3.2.4) % of your organization's total facilities within direct operations exposed to water-related risk in this river basin

Select from:

☑ 1-25%

(3.2.10) % organization's total global revenue that could be affected

Select from:

☑ Unknown

(3.2.11) Please explain

In 2024, Amgen identified several sites in our operations, including Puerto Rico, that are in water-stressed areas using the WWF Water Risk Filter and WRI Aqueduct tools. Using the WWF Water Risk Filter's Basin Risk Results, we identified Amgen sites with water stress using the Basin Physical Risk "Risk Score Classification" of 2.6 or higher (Medium Risk or Higher). Using the WRI Aqueduct Water Risk Atlas tool, we identified Amgen sites with water stress using a Water Stress Score of "Medium-High" (20-40%) or higher. According to the WWF Water Risk Filter tool, our Puerto Rico facility is located in a region with Medium Physical Basin Risk. The Physical Basin Risk category includes water availability, drought, flooding, water quality, and ecosystem services. Our Puerto Rico facility has on-site wells and a wastewater treatment plant that treats and reuses water for industrial purposes, reducing reliance on municipal water, including, for example, during an emergency. Puerto Rico's island location in the Caribbean exposes its inbound and outbound value chain transiting through the region to increased Cyclone/hurricane/typhoon and Flooding risk in addition to its own locational risk in those categories. These natural disasters may continue to affect properties and the electric grid and communications networks.

Row 2

(3.2.1) Country/Area & River basin

United States of America

☑ Other, please specify :North Pacific Ocean Basin

(3.2.2) Value chain stages where facilities at risk have been identified in this river basin

Select all that apply

☑ Direct operations

(3.2.3) Number of facilities within direct operations exposed to water-related risk in this river basin

2

(3.2.4) % of your organization's total facilities within direct operations exposed to water-related risk in this river basin

Select from:

☑ 1-25%

(3.2.10) % organization's total global revenue that could be affected

Select from:

☑ Unknown

(3.2.11) Please explain

In 2024, Amgen identified several sites in our operations that are in water-stressed areas using the WWF Water Risk Filter and WRI Aqueduct tools, including Amgen's Thousand Oaks and San Francisco facilities. Using the WWF Water Risk Filter's Basin Physical Risk Results, we identified Amgen sites with water stress using the "Risk Score Classification" of 2.6 or higher (Medium Risk or Higher). According to the WWF Water Risk Filter tool, our Thousand Oaks facility is located in a region with High Physical Basin Risk and our San Francisco facility is located in a region with Medium Physical Basin Risk. The Physical Basin Risk category includes water availability, drought, flooding, water quality, and ecosystem services. To reduce the risk associated with water scarcity, Amgen has implemented multiple measures, including innovative improved reverse osmosis technologies, manufacturing process improvement such as clean-in-place (CIP) cycles, and landscape improvements to significantly reduce water consumption. Amgen is in the design phase of a campus-wide project to treat and reuse cooling tower blowdown and reverse osmosis reject wastewater to reduce water needs.

Row 3

(3.2.1) Country/Area & River basin

United States of America

☑ Other, please specify :North Atlantic (447)

(3.2.2) Value chain stages where facilities at risk have been identified in this river basin

Select all that apply

☑ Direct operations

(3.2.3) Number of facilities within direct operations exposed to water-related risk in this river basin

3

(3.2.4) % of your organization's total facilities within direct operations exposed to water-related risk in this river basin

Select from:

☑ 1-25%

(3.2.10) % organization's total global revenue that could be affected

Select from:

☑ Unknown

(3.2.11) Please explain

In 2024, Amgen identified several sites in our operations that are in water-stressed areas using the WWF Water Risk Filter and WRI Aqueduct Tools, including West Greenwich, Rhode Island, and Cambridge, Massachusetts. Using the WWF Water Risk Filter's Basin Physical Risk Results, we identified Amgen sites with water stress using the "Risk Score Classification" of 2.6 or higher (Medium Risk or Higher). Using the WRI Aqueduct Water Risk Atlas tool, we identified Amgen sites with Water Stress using a Water Stress Score of "Medium-High" (20-40%) or higher. According to the WWF Water Risk filter Tool, our Rhode Island facility and our Massachusetts facility are both located in a region with Medium Physical Basin Risk. The Physical Basin Risk category includes water availability, drought, flooding, water quality, and ecosystem services. Feasibility and design studies for the potential implementation of on-site wastewater treatment plants are underway for our Rhode Island and Massachusetts facilities that would then enable these sites to capture and reuse an increased amount of water from the facilities' operations, reducing local demand for municipal water, as water issues are highly localized to each geographic location.

Row 4

(3.2.1) Country/Area & River basin

United States of America

☑ Mississippi River

(3.2.2) Value chain stages where facilities at risk have been identified in this river basin

Select all that apply

☑ Direct operations

(3.2.3) Number of facilities within direct operations exposed to water-related risk in this river basin

1

(3.2.4) % of your organization's total facilities within direct operations exposed to water-related risk in this river basin

Select from:

☑ 1-25%

(3.2.10) % organization's total global revenue that could be affected

Select from:

☑ Unknown

(3.2.11) Please explain

In 2024, Amgen identified several sites in our operations that are in water-stressed areas using the WWF Water Risk Filter and WRI Aqueduct tools, including Deerfield, Illinois, a site integrated from the 2023 Horizon Therapeutics plc acquisition. According to the WWF Water Risk Filter tool, our Deerfield, IL facility is located in a region with Medium Physical Basin Risk. The Physical Basin Risk category includes water availability, drought, flooding, water quality, and ecosystem services.

Row 5

(3.2.1) Country/Area & River basin

Singapore

☑ Other, please specify :Malay Peninsula (526)

(3.2.2) Value chain stages where facilities at risk have been identified in this river basin

Select all that apply

☑ Direct operations

(3.2.3) Number of facilities within direct operations exposed to water-related risk in this river basin

1

(3.2.4) % of your organization's total facilities within direct operations exposed to water-related risk in this river basin

Select from:

☑ 1-25%

(3.2.10) % organization's total global revenue that could be affected

Select from:

☑ Unknown

(3.2.11) Please explain

In 2024, Amgen identified several sites in our operations that are in water-stressed areas using the WWF Water Risk Filter and WRI Aqueduct tools, including our manufacturing facility in Singapore. According to the WWF Water Risk Filter tool, our Singapore facility is located in a region with Medium Physical Basin Risk. The Physical Basin Risk category includes water availability, drought, flooding, water quality, and ecosystem services. Many of our operations and facilities, including those essential to our manufacturing, R&D, and distribution activities, are in locations that are subject to natural disasters, including droughts, fires, extreme temperatures, hurricanes, tropical storms, and floods. The severity and frequency of weather-related natural disasters has been amplified by, and is expected to continue to be amplified by, global climate change. Such natural disasters have caused, and in the future may cause, damage to and/or disrupt our operations, which may result in a material adverse effect on our product sales, business, and results of operations. Our suppliers, vendors, and business partners also face similar risks, and any disruption to their operations could have an adverse effect on our supply and manufacturing chain. Many of our key facilities are located on islands, including Puerto Rico, Singapore, and Ireland, which rely on essential port facilities that may be vulnerable to climate change-related or other natural disasters. Although we have detailed business continuity plans in place and periodic assessments of our natural disaster risk, any natural disaster may also result in prolonged interruption to our critical operational and business activities, and we may be required to incur significant costs to remedy the effects of such natural disasters and fully resume operations, which may result in a material adverse effect on our product sales, business, and results of operations.

Row 6

(3.2.1) Country/Area & River basin

Netherlands

☑ Other, please specify :North Sea

(3.2.2) Value chain stages where facilities at risk have been identified in this river basin

Select all that apply

☑ Direct operations

(3.2.3) Number of facilities within direct operations exposed to water-related risk in this river basin

1

(3.2.4) % of your organization's total facilities within direct operations exposed to water-related risk in this river basin

Select from:

☑ 1-25%

(3.2.10) % organization’s total global revenue that could be affected

Select from:

☑ Unknown

(3.2.11) Please explain

In 2024, Amgen identified several sites in our operations that are in water-stressed areas using the WWF Water Risk Filter and WRI Aqueduct tools, including our manufacturing facility in Breda, Netherlands. Using the WWF Water Risk Filter’s Basin Physical Risk Results, we identified Amgen sites with water stress using the “Risk Score Classification” of 2.6 or higher (Medium Risk or Higher).

Row 7

(3.2.1) Country/Area & River basin

United Kingdom of Great Britain and Northern Ireland

☑ Other, please specify :North Sea

(3.2.2) Value chain stages where facilities at risk have been identified in this river basin

Select all that apply

☑ Direct operations

(3.2.3) Number of facilities within direct operations exposed to water-related risk in this river basin

1

(3.2.4) % of your organization’s total facilities within direct operations exposed to water-related risk in this river basin

Select from:

☑ 1-25%

(3.2.10) % organization’s total global revenue that could be affected

Select from:

☑ Unknown

(3.2.11) Please explain

In 2024, Amgen identified several sites in our operations that are in water-stressed areas using the WWF Water Risk Filter and WRI Aqueduct tools, including our administrative facility in Cambridge, United Kingdom. Using the WWF Water Risk Filter's Basin Risk Results, we identified Amgen sites with water stress using the "Risk Score Classification" of 2.6 or higher (Medium Risk or Higher).

Row 8

(3.2.1) Country/Area & River basin

Canada

☑ Fraser River

(3.2.2) Value chain stages where facilities at risk have been identified in this river basin

Select all that apply

☑ Direct operations

(3.2.3) Number of facilities within direct operations exposed to water-related risk in this river basin

1

(3.2.4) % of your organization's total facilities within direct operations exposed to water-related risk in this river basin

Select from:

☑ 1-25%

(3.2.10) % organization's total global revenue that could be affected

Select from:

☑ Unknown

(3.2.11) Please explain

In 2024, Amgen identified several sites in our operations that are in water-stressed areas using the WWF Water Risk Filter and WRI Aqueduct tools, including our laboratory facility in Burnaby, Canada. Using the WWF Water Risk Filter's Basin Physical Risk Results, we identified Amgen sites with water stress using the "Risk Score Classification" of 2.6 or higher (Medium Risk or Higher).

Row 9

(3.2.1) Country/Area & River basin

United States of America

☑ Other, please specify :Ohio River Basin

(3.2.2) Value chain stages where facilities at risk have been identified in this river basin

Select all that apply

☑ Direct operations

(3.2.3) Number of facilities within direct operations exposed to water-related risk in this river basin

2

(3.2.4) % of your organization's total facilities within direct operations exposed to water-related risk in this river basin

Select from:

☑ 1-25%

(3.2.10) % organization's total global revenue that could be affected

Select from:

☑ Unknown

(3.2.11) Please explain

In 2024, Amgen identified several sites in our operations that are in water-stressed areas using the WWF Water Risk Filter and WRI Aqueduct tools, including our manufacturing facility in New Albany, Ohio. Using the WRI Aqueduct's Water Risk Atlas tool, we identified our facility in Ohio as having Medium-High baseline water stress.

Row 10

(3.2.1) Country/Area & River basin

Ireland

☑ Other, please specify :Ireland Basin

(3.2.2) Value chain stages where facilities at risk have been identified in this river basin

Select all that apply

☑ Direct operations

(3.2.3) Number of facilities within direct operations exposed to water-related risk in this river basin

2

(3.2.4) % of your organization's total facilities within direct operations exposed to water-related risk in this river basin

Select from:

☑ 1-25%

(3.2.10) % organization's total global revenue that could be affected

Select from:

☑ Unknown

(3.2.11) Please explain

Many of our operations and facilities, including those essential to our manufacturing, R&D, and distribution activities, are in locations that are subject to natural disasters, including droughts, fires, extreme temperatures, hurricanes, tropical storms, and floods. The severity and frequency of weather-related natural disasters has been amplified by, and is expected to continue to be amplified by, global climate change. Such natural disasters have caused, and in the future may cause,

damage to and/or disrupt our operations, which may result in a material adverse effect on our product sales, business, and results of operations. Our suppliers, vendors, and business partners also face similar risks, and any disruption to their operations could have an adverse effect on our supply and manufacturing chain. Many of our key facilities are located on islands, including Puerto Rico, Singapore, and Ireland, which rely on essential port facilities that may be vulnerable to climate change-related or other natural disasters. Although we have detailed business continuity plans in place and periodic assessments of our natural disaster risk, any natural disaster may also result in prolonged interruption to our critical operational and business activities, and we may be required to incur significant costs to remedy the effects of such natural disasters and fully resume operations, which may result in a material adverse effect on our product sales, business, and results of operations.
[Add row]

(3.3) In the reporting year, was your organization subject to any fines, enforcement orders, and/or other penalties for water-related regulatory violations?

	Water-related regulatory violations	Comment
	Select from: ☑ No	*Amgen did not receive any fines, enforcement orders, or other penalties for water-related regulatory violations in 2024.*

[Fixed row]

(3.5) Are any of your operations or activities regulated by a carbon pricing system (i.e. ETS, Cap & Trade or Carbon Tax)?

Select from:
☑ Yes

(3.5.1) Select the carbon pricing regulation(s) which impact your operations.

Select all that apply
☑ BC carbon tax
☑ California CaT - ETS
☑ Ireland carbon tax
☑ Singapore carbon tax

☑ Other carbon tax, please specify :UK Climate Change Levy

(3.5.2) Provide details of each Emissions Trading Scheme (ETS) your organization is regulated by.

California CaT - ETS

(3.5.2.1) % of Scope 1 emissions covered by the ETS

0

(3.5.2.2) % of Scope 2 emissions covered by the ETS

0

(3.5.2.3) Period start date

01/01/2024

(3.5.2.4) Period end date

12/31/2024

(3.5.2.5) Allowances allocated

8768

(3.5.2.6) Allowances purchased

0

(3.5.2.7) Verified Scope 1 emissions in metric tons CO2e

21869

(3.5.2.8) Verified Scope 2 emissions in metric tons CO2e

0

(3.5.2.9) Details of ownership

Select from:

☑ Facilities we own and operate

(3.5.2.10) Comment

Currently, Amgen's facility located in Thousand Oaks, California, is deemed a General Market Participant - Previously Covered under the California Air Resources Board (CARB) Cap-and-Trade Program. Please note that the reported allowances were allocated in 2014 as compliance instruments and have not been sold or exchanged; hence, they still remain in our active account balance. The regulation defines a General Market Participant as an organization that does not meet the requirements of a Covered Entity or an Opt-in Covered Entity and that intends to purchase, hold, sell, or voluntarily retire compliance instruments.
[Fixed row]

(3.5.3) Complete the following table for each of the tax systems you are regulated by.

BC carbon tax

(3.5.3.1) Period start date

01/01/2024

(3.5.3.2) Period end date

12/31/2024

(3.5.3.3) % of total Scope 1 emissions covered by tax

0

(3.5.3.4) Total cost of tax paid

39944.3

(3.5.3.5) Comment

Carbon tax applied to natural gas consumption at our Burnaby, British Columbia facility in Canada.

Ireland carbon tax

(3.5.3.1) Period start date

01/01/2024

(3.5.3.2) Period end date

12/31/2024

(3.5.3.3) % of total Scope 1 emissions covered by tax

2.77

(3.5.3.4) Total cost of tax paid

269758.92

(3.5.3.5) Comment

Carbon tax applied to natural gas consumption at our Dun Laoghaire and Waterford facilities.

Singapore carbon tax

(3.5.3.1) Period start date

01/01/2024

(3.5.3.2) Period end date

12/31/2024

(3.5.3.3) % of total Scope 1 emissions covered by tax

0

(3.5.3.4) Total cost of tax paid

0

(3.5.3.5) Comment

As a reportable but not taxable facility, Amgen Singapore does not have a carbon tax liability, being well under the 25,000 tCO2e annual threshold.

Other carbon tax, please specify

(3.5.3.1) Period start date

01/01/2024

(3.5.3.2) Period end date

12/31/2024

(3.5.3.3) % of total Scope 1 emissions covered by tax

0

(3.5.3.4) Total cost of tax paid

5432.49

(3.5.3.5) Comment

UK Climate Change Levy applied to electricity consumption (Scope 2) at our Cambridge facility in Great Britain. Fees are in pound sterling and were converted to USD as of December 31, 2024.
[Fixed row]

(3.5.4) What is your strategy for complying with the systems you are regulated by or anticipate being regulated by?

Amgen has developed a database of current and impending global, EU, country-wide, and local carbon and climate change regulations. This database identifies associated requirements, applicability to Amgen, and timelines to help maintain compliance. Amgen has also engaged a third-party firm to conduct certain global sustainability regulation scanning to support our awareness of pending and approved reporting requirements applicable to Amgen entities. Amgen is also participating in multiple industry-specific task groups that focus on tracking and addressing climate-related regulations. As applicable regulations come into force, Amgen has established multifunctional teams to address compliance with such requirements. For example, Amgen has allocated resources to comply with the Carbon Border Adjustment Mechanisms regulations. Amgen has set carbon neutrality and supplier engagement targets through 2027 that were approved by the SBTi in August 2022, in part, to help meet the requirements of current and proposed carbon regulations and pricing systems. Amgen continues to reduce its own emissions through innovation and efficiency. Amgen has created a streamlined, more economical plant blueprint for biomanufacturing that is considerably more sustainable compared to conventional manufacturing plant design. Amgen Ecovation™ is our approach to innovative and sustainable manufacturing, which we integrate into the upfront design, development, and execution of new laboratory, manufacturing, and administrative buildings. This innovative approach has enabled Amgen to reduce plant energy consumption by over 70% compared to legacy conventional manufacturing processes (as of September 30, 2024, for our manufacturing facilities located in Rhode Island and Singapore). Amgen has also established two forms of an internal price on carbon (IPoC) to encourage the design and implementation of projects that reduce energy use and carbon emissions. Across our value chain, Amgen is engaging, and will continue to engage, with our suppliers on their own decarbonization efforts to mitigate carbon tax risk. Amgen is also a sponsor of the global pharmaceuticals industry Energize program, aimed at accelerating adoption of renewable energy and reducing GHG emissions among suppliers. This first-of-its-kind industry program will train pharmaceutical suppliers on renewable energy adoption and increase access to renewable energy sourcing. This gives suppliers – who may not otherwise have the internal resources or expertise available – the opportunity to participate in the market for power purchase agreements (PPAs).

(3.6) Have you identified any environmental opportunities which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future?

	Environmental opportunities identified
Climate change	*Select from:* ☑ Yes, we have identified opportunities, and some/all are being realized
Water	*Select from:* ☑ Yes, we have identified opportunities, and some/all are being realized

[Fixed row]

(3.6.1) Provide details of the environmental opportunities identified which have had a substantive effect on your organization in the reporting year, or are anticipated to have a substantive effect on your organization in the future.

Climate change

(3.6.1.1) Opportunity identifier

Select from:

☑ Opp1

(3.6.1.3) Opportunity type and primary environmental opportunity driver

Resource efficiency

☑ Increased efficiency of production and/or distribution processes

(3.6.1.4) Value chain stage where the opportunity occurs

Select from:

☑ Direct operations

(3.6.1.5) Country/area where the opportunity occurs

Select all that apply

☑ Canada

☑ Ireland

☑ Singapore

☑ Netherlands

☑ Puerto Rico

☑ United States of America

(3.6.1.8) Organization specific description

Situation: Amgen has created a streamlined, more economical plant blueprint for biomanufacturing that is considerably more sustainable compared to conventional manufacturing plant design. Amgen Ecovation™ is our approach to innovative and sustainable manufacturing, which we integrate into the upfront design,

development, and execution of new laboratory, manufacturing, and administrative buildings. This innovative approach has enabled Amgen to reduce plant energy consumption by over 70% compared to legacy conventional manufacturing processes (as of September 30, 2024, for our manufacturing facilities located in Rhode Island and Singapore), while increasing reliability. We pioneered this approach with our biomanufacturing plants in Singapore and Rhode Island (USA). Task: The approach was incorporated into our new facilities in Ohio and North Carolina (USA). Result: Amgen's Ohio and North Carolina plants are expected to decrease their associated carbon footprint by over 4,665 metric tons per year compared to American Society of Heating, Refrigerating and Air-Conditioning Engineer (ASHRAE) industry standards.

(3.6.1.9) Primary financial effect of the opportunity

Select from:

☑ Reduced indirect (operating) costs

(3.6.1.10) Time horizon over which the opportunity is anticipated to have a substantive effect on the organization

Select all that apply

☑ Short-term

(3.6.1.11) Likelihood of the opportunity having an effect within the anticipated time horizon

Select from:

☑ Virtually certain (99–100%)

(3.6.1.12) Magnitude

Select from:

☑ Medium-high

(3.6.1.14) Anticipated effect of the opportunity on the financial position, financial performance and cash flows of the organization in the selected future time horizons

Reduced operating costs

(3.6.1.15) Are you able to quantify the financial effects of the opportunity?

Select from:

☑ No

(3.6.1.25) Explanation of cost calculation

The cost includes construction costs spent on buildings and sites that incorporated Amgen Ecovation(TM), including our Singapore, Rhode Island, North Carolina, and Ohio facilities.

(3.6.1.26) Strategy to realize opportunity

Our application of Amgen Ecovation(TM) is aligned with our 2027 carbon neutrality goal. Amgen also has SBTi-approved targets that include reducing absolute Scope 1 and 2 greenhouse gas emissions 55% by 2027 from a 2019 baseline, increasing annual sourcing of renewable electricity from 29% in 2019 to 100% by 2027, and thereafter annually sourcing 100% renewable electricity through 2030. We incorporated Amgen Ecovation(TM) into our new Ohio and North Carolina (USA) facilities. Amgen performed project life cycle assessment and enhanced commissioning for the mechanical systems and building envelopes at our Ohio and North Carolina facilities. Energy models and mass balances were used to identify resource utilization and analyze design and operation for environmental sustainability opportunities. Our Ohio facility was designed to be fully electrified to eliminate Scope 1 emissions. Ground-mounted solar projects are being installed at both sites, with an additional roof-mounted system in North Carolina. Submeters have also been installed on utilities systems to improve real-time tracking of energy use, identify losses, and optimize system performance. Additionally, in 2024, Amgen's San Francisco R&D facility relocated into a LEED certified building, resulting in significant carbon savings from a modern cooling tower, low-flow fixtures, and SmartStack (TM) system adaptations driving efficiency.

Water

(3.6.1.1) Opportunity identifier

Select from:

☑ Opp2

(3.6.1.3) Opportunity type and primary environmental opportunity driver

Capital flow and financing

☑ Access to new financing options

(3.6.1.4) Value chain stage where the opportunity occurs

Select from:

☑ Direct operations